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RESTRICTION ENZYME GENERATED NEXT-GENERATION SEQUENCING
LIBRARIES AND GENETIC RISK MODIFIERS OF BRCA1 MUTATION
CARRIERS
Bradley M. Downs, Ph.D.
University of Nebraska, 2016
Supervisor: San Ming Wang, M.D.
Next-generation sequencing (NGS) is a high throughput technique used to sequence
large amounts of DNA in a short amount of time. However, a limitation to NGS is that
the generated data is in a single consensus sequence without distinguishing between
variants on homologous chromosomes. Separating or phasing the variants from the
maternal and paternal chromosomes can provide information about the genetic origin of
disease and information about how DNA nucleotide alterations interact in cis.

This

dissertation explores a new technical method of using restriction enzymes during NGS
library preparation and its ability to increase the amount of phasing information that can
be derived from NGS data. This study provides evidence that increasing the fragment
size of NGS libraries can increase the amount of variant phasing information derived
from NGS data.
BRCA1 is a well-known tumor suppressor that, when mutated, predisposes the mutation
carrier to breast cancer. BRCA1 mutation carriers have a 44-75% risk of developing
breast cancer by age 70. In this study, we used next-generation sequencing data to
identify germline genetic variants that modify the risk of breast cancer in BRCA1
mutation carriers. With the use of both biological and statistical filters, five variants were
identified that changed breast cancer risk in BRCA1 mutation carriers. Furthermore, it
was shown that two of the affected genes alter the growth of BRCA1 mutation breast cell

	
  
lines. Perhaps, more importantly, the two variants were shown to alter the function of
the affected genes.

This is the first study to provide functional evidence on how

common genetic variants can modify the risk of breast cancer in BRCA1 mutation
carriers. 	
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The human genome
The genome is comprised of all the genetic material encoded as DNA. For humans
(Homo sapiens), the genome is comprised of 23 chromosome pairs (44 autosomes and
2 sex chromosomes) as well as mitochondria DNA. Every cell within the human body
with a nucleus has 46 chromosomes, with the exception of germ cells. Germ cells have
a haploid genome comprised of 23 chromosomes.
The human genome can be divided into coding and noncoding sequences. Coding DNA
sequences occupy ~2% of the genome and can be transcribed into mRNA which is then
translated into proteins. Coding regions are called exons while the noncoding regions
are called introns, untranslated regions (UTRs), and noncoding exons (NC-Exon). Once
a coding region is transcribed into precursor mRNA (pre-mRNA), the primary transcript
is converted into mature mRNA by the capping of a 7-methylguanosine residue to the 5’
terminal end, polyadenylation of the 3’ terminal end, and splicing of the introns.
Noncoding DNA do not encode protein but may contain genes that are transcribed into
functional RNA molecules such as ribosomal RNA and microRNAs. Noncoding DNA
sequences can also bind transcription factors (ie enhancers, insulators, promoters, etc),
which can regulate gene expression and/or genomic stability.
The human Genome project
Prior to the Human Genome Project, very little was known about the contents of the
human genome. The Human Genome Project began in 1990, took thirteen years and
roughly ~3 billion dollars to complete. The goal for this project was to, for the first time,
sequence the entire human genome. The Project sequenced ~3 billion base pairs and
~20,500 genes in the genome (http://www.genome.gov/12011238).

The information
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gained from this project was largely used to construct the human reference genome
many bioinformatics laboratories still use today.
Sanger sequencing
The Human Genome Project relied on the sequencing technique developed by Frederick
Sanger in 1977 1 . The Sanger method relies on electrophoretic separation of mixtures
of randomly terminated extension products. This type of sequencing uses an automated
method of fluorescently labeled terminators, capillary electrophoresis separation, and
automated laser signal detection for improved nucleotide sequence detection.
biggest disadvantage of this method is the slow throughput.

The

Despite this, Sanger

sequencing utilizes well-defined chemistry, making it the most accurate method for
sequencing currently available.
Next generation sequencing
In 2004, The National Human Genome Research Institute (NHGRI) initiated a funding
program with the aim to reduce cost of genome sequencing.

The current high-

throughput DNA sequencing technologies frequently used today is next-generation
sequencing (NGS) and massive-parallel sequencing.

All NGS platforms monitor the

sequential addition of nucleotides to immobilize and spatially array DNA templates but
differ substantially in how these templates are generated and how they are interrogated
to reveal their sequences 2 . The increased throughput of NGS reactions comes at the
cost of read length of 30-400bp compared to Sanger sequencing, which can read 0.51kb. Because of the short reads, NGS uses resequencing, which compares the density
and sequence content of shorter reads to a reference genome to make the genome
map.

The human reference genomes being used today, hg19 and b37, are largely

constructed from the results of the Human Genome Project.
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Illumina Sequencing
All NGS requires the starting material to be converted into a library of sequencing
reaction templates first (the size of which depends on each sequencing platform’s
specifications). Next, platform-specific synthetic DNA adapters are then ligated to the
end of the library fragments. Depending on the NGS technology, the NGS library is
either sequenced directly or is amplified first, then sequenced.
The only NGS platform used in this dissertation was an Illumina HiSeq based NGS. The
Illumina HiSeq platform technology uses genomic DNA hybridization and bridge
amplifies on its specific grafted flowcell. Bridge amplification on the specific grafted
flowcell is unique to Illumina NGS technology. After the genomic library is annealed and
clonally amplified, a fluorescently labeled reversible terminator is imaged as the dNTPs
are
added 3 (Figure 1).
It is also possible to capture targeted genomic sequences within the NGS library.
Arguably, the most widely used targeted sequencing method is exome capturing. These
targeted regions are first hybridized by DNA bound biotinylated probes. The biotinylated
probes can then be captured with the selected target regions 3 (Figure 2). Sequencing
only the exons, ~2% of the genome, saves on cost and increases the rate of data
processing.
While NGS has fast throughput, it is difficult to align higher levels of diversity to the
reference genome because of the short reads. This issue is combated through the use
of longer read lengths or paired-end/mate-pair sequencing 4 .

Length selection and the

options of paired-end or singled-end sequencing are options on HiSeq sequencing
systems. Once the sequencing run is complete, computational tools are needed analyze
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the quality of each called nucleotide and to map the sequences to the reference
genome.

~150%200'bp'fragments'

Apply'to'ﬂowcell'
A4ach'adapters''
to'create''
sequencing'
library'

Cluster'generaAon''
by'solid'phase'PCR''
(bridge'ampliﬁcaAon)'

Sequencing)by)synthesis)with)reversible)terminators)

Figure 1. Illumina based genomic library construction and Illumina HiSeq based
NGS. Once the genomic DNA is sheared to the correct fragment size, the adapters are
attached to the sequenced library. The constructed library is then applied to the flow cell
and clutters are generated by bridge amplification. After amplification, a fluorescently
labeled reversible terminator is imaged as the dNTPs are added 3 .
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Figure 2. Exome capture with the Illumina HiSeq based NGS. Once the genomic
DNA is processed to an appropriate fragment size, DNA bound biotinylated probes are
hybridized to the fragmented DNA. Next, the probes are pulled down and the captured
DNA is sequenced on the Illumina HiSeq platform 3 .
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Computational steps used to align Illumina sequenced reads
Once the sequencing data from the HiSeq run are collected, the low quality sequences,
which could lead to poor mapping and false positive variant calling need to be removed.
Quality of sequencing decreases the further the reads are sequenced therefore, Illumina
recommends that a percentage of the read ends be trimmed. This percentage is based
on the length of read during sequencing. After the low quality sequences are removed,
software can align the reads to the reference genome. To increase the accuracy of
insertions, deletions, and repetitive regions of the genome, the reads need to be locally
realigned. If the library was amplified via PCR before sequencing, the duplicates must
be marked to remove errors that might have arisen during the PCR amplification
process. The variations between the sequenced library and the reference genome can
now be called. The next step is to annotate the called variants. Depending on the type
of study and the investigator hypothesis, these annotated variants will be analyzed
further in a study specific manner.
The cancer genome
Cancer results when the body is unable to regulate cellular growth. The study of cancer
genomes can be divided into two fields of study (i) germline mutations that change the
risk of developing cancer and (ii) somatic genomic alterations that contribute to
tumorigenesis, invasion, metastasis, and relapse.
Somatic mutations are any alterations of the germline DNA sequence in the genome,
which can be separated into passenger and driver mutations.

Driver mutations are

mutations of the DNA that gives a selective advantage to a cancer cell. Passenger
mutations are mutations that have no fitness effect but may be linked to the genome with
driver mutations.
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Germline mutations are found in every genome within the body and can be passed down
in a hereditary fashion. In the general population, familial predispositions for cancer is
rare, giving evidence that germline mutations that increase the predisposition for cancer
must also be rare. The frequency of minor alleles can be defined by the minor allele
frequency (MAF). The MAF refers to the frequency at which the allele occurs in a given
population. Alleles with a MAF higher than 1 percent are usually considered common
alleles while a MAF lower than 1 percent is considered rare 5 . While the rarity of the
mutation is an important factor when searching for mutations that influence cancer
development, the mutation’s effect on the cell is also an important factor to consider
when investigating cancer related germline or somatic mutations.
Mutations can be categorized by the effect they have on the protein they affect.
Because of the redundancy of codons (multiple codons can translate the same amino
acid), silent or synonymous mutations are changes to the DNA nucleotide that do not
cause a change in amino acid. Missense or nonsynonymous mutations cause a change
in the translated amino acid. Splice mutations affect mRNA processing and can cause
deletion of exonic translation. Nonsense or stop gain mutations change the amino acid
codon into a stop codon leading to a truncated protein product. The last type of mutation
is frame shifts or out of frame insertions or deletions. This type of mutation generally
causes a premature stop codon, generating a truncated protein. Nonsense and frame
shift mutations generally have the largest effect on the translated protein.
software packages can predict the effects of missense mutations.

Many

However, these

mutations are generally considered variants of unknown significance until the mutations
undergo rigorous statistical analysis and/or the effects of the mutation are investigated
by functional assays.
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Breast cancer
Breast cancer is the most frequent cancer diagnosis in women with an estimated 1.38
million new diagnoses worldwide in 2008

6

.

In the United States, the chance of a

woman being diagnosed with breast cancer during her lifetime is one in eight 7 . About
10% of women diagnosed with breast cancer have a hereditary predisposition for breast
cancer 8,9 . BRCA1 and BRCA2 are the most common autodominant predisposition for
hereditary breast cancer and also the most well studied, comprising ~20% of all familial
breast cancer cases.

Interestingly, ~50% of the familial breast cancer cases have an

unknown predisposition mutation and are thus labeled as BRCAx 10 (Figure 3).
This dissertation covers a wide range of topics including analyzing new methods of NGS
library construction, investigating potentially new breast cancer predisposition mutations
and the identification and characterization of genetic germline modifiers that change the
risk of developing breast cancer in BRCA1 mutation carriers.
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BRCA1)

9%#
11%#
Cases)with)germline)
mutaEons)10%)

6%#

50%#

Sporadic)90%)

14%#

BRCA2)

1%#

TP53/STK11/CDH1/PTEN)
CHEK2/ATM/BRIP/PLB)
GWAS)SNPs)
iCOG)esEmated)

9%#

other)) BRCAx)

Figure 3. Hereditary predispositions of breast cancer. All breast cancer cases can
be separated into sporadic cases and cases with germline predisposition mutations.
Mutations in the BRCA genes comprise 20% of all familial breast cancers. The other
cases have an unknown genetic predisposition and are thus labeled as BRCAx 10,11 .
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CHAPTER 1: Restriction enzyme generated next-generation sequencing libraries
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1.1 Introduction
1.1.1 Current limitations of NGS ability to phase the human genome
Homo sapiens genomes are diploid, receiving one chromosome copy from their mother
and one copy form their father.

Genome phasing is the process of separating the

maternal and paternal chromosomes from a single genome. Information derived from
genomic phasing can provide the genetic origin of disease and information about how
DNA nucleotide alterations interact in cis. Currently, most sequencing techniques
generate a single consensus sequence without distinguishing between variants on
homologous chromosomes.
Since the conception of next generation sequencing, both the throughput and
sequencing read length has increased substantially. However, even with the advances
of NGS technology, the biggest disadvantage of NGS system is the relatively short read
length of 30-400bp, depending on the NGS platform. Due to the short read length, NGS
relies on the method of resequencing to map the reads to the correct position on the
reference genome. While this method has been shown to accurately map sequenced
reads to a reference genome, it is unable to phase the sequenced chromosomes.
1.1.2 Phase information derived from NGS
Once the genomic libraries are sequenced on the Illumina HiSeq 2000 platform, there
are 3 NGS read combinations that can be used to construct contigs and provide variant
phasing information; variants can be phased i) in the same read, ii) in different reads, or
iii) by paired reads (Figure 4). These 3 NGS read combinations can be integrated to
phase multiple variants on a single contig.

	
  

13

i)#

ii)#

iii)#
Figure 4. Next-generation sequencing read combinations providing variant
phasing information. The three next generation sequencing reads that can be used to
construct contigs and provide variant phasing information are i) variants phased in the
same read, ii) variants phased in different reads, iii) variants phased in pair-end reads.
Red lines represent called variants.

	
  

14

1.1.3 Computational and experimental approaches to phase the genome
There are two NGS approaches used for phasing the genome: computational and
experimental.

Experimental approaches attempt to phase the genome prior to

sequencing and relies on the physical separation of the chromosomes.
computational approach attempts to phase the genome post-sequencing.

The

This method

uses statistics to estimate the probability that two variants are linked and thus providing
phase information.

Computational phasing is mostly used to reconstruct haplotypes

within a single pedigree.

Neither computational nor experimental approaches are

commonly used because they are thought to be too experimentally laborious and/or
computationally underpowered. In the following project, we propose the use of a new
experimental approach that is not experimentally laborious and has the potential to
improve the ability of NGS to phase the genome.
1.1.4 Using restriction enzymes to construct NGS libraries
There are two types of experimental approaches that can be used to increase the
phasing ability of next-generation sequencing. One can either i) improve NGS platform
technology so longer reads can be sequenced or ii) redesign the method of genomic
library construction.

This study will investigate a new method of genomic library

construction.
Currently, the process of making a genomic library is as follows: DNA shearing by
sonication, ligation of adapters, selection of exons (if preferred), selection of size, and
sequencing of DNA library (Figure 1). We propose that if DNA were specifically cut with
restriction enzymes, instead of random shearing, there would be a two-fold effect: i) the
library construct size would be more variable which will increase the size of overlapping
sequenced data (contigs) and thus increase the number of phased variants and ii) the
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number of variant errors due to low quality reads will decrease with the new ability to
filter low quality reads lacking restriction sites.
1.1.5 Selection of restriction enzyme
The Illumina HiSeq 2000 platform has an optimal fragment sequencing length of 150200 base pairs. The accuracy of the Illumina system to sequence reads decreases with
fragments sizes larger than 200 bases pairs. Because of this limitation, the restriction
enzymes chosen for genomic DNA digestion must be selected based on average
digestion fragment length. Furthermore, because restriction digest sites are fixed, unlike
random shotgun sequencing, multiple restriction enzyme libraries will need to be pooled
to get adequate genomic coverage. Based on the average genomic digestion fragment
length, 4 restriction enzymes, MluC1, Alu1, HypCH4V, and Fat1 were selected to
generate 4 different restriction enzyme fragmented NGS libraries (Table 1).

To

increases the rate of data processing, all of the restriction enzyme NGS libraries
underwent exome capture before being sequenced on the Illumina HiSeq 2000.
1.1.6 Genomic DNA sample selection
Parents and offspring trios are commonly used in phasing experiments due to the ability
to track inherited variants in the offspring.

Because we are interested in genome

phasing, we decided to use the genomic DNA from a daughter of a trio (daughter
NA19240, mother NA19238 and father NA19239), which were collected during the 1000
Genomes project.

This daughter, NA19240, was chosen because the parents’ and

daughter’s variants have already been identified and are freely available from the
Complete Genomic database.

Furthermore, the daughters genomic DNA is

commercially available. The daughters exome has also been captured using the same
exome capture kit and ran on the same NGS platform (Illumina HiSeq 2000) as the
libraries made with the restriction enzymes.
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Table 1. Average genomic digested fragment length by restriction enzyme

Restriction enzyme

MluCI

AluI

HypCH4V

FatI

Illumina HiSeq
2000
suggested
fragment
length

Recognized bases

|AATT
TTAA|

AG|CT
TC|GA

TG|CA
AC|GT

|CATG
GTAC|

-

Average digested
fragment length

144

241

216

225

150-200

|, cutting site of restriction enzyme
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This raw sequenced data is freely available for download from the Complete Genomic
database. To compare the two methods of NGS library construction accurately, we ran
both the raw data from the restriction enzyme libraries and the raw data from the
Complete Genomic database in parallel through a single bioinformatics pipeline.
It was hypothesized that the NGS libraries constructed with fragments generated by
restriction enzyme would be more variable in size in comparison to libraries generated
from sonication. This variability of fragment size was predicted to increase the contig
size and thus increase the number of phased variants. It was also hypothesized that
number of variant errors due to low quality reads will decrease in the restriction enzyme
generated NGS libraries in comparison to libraries generated by sonication because of
the unique ability to filter low quality reads that lacked restriction sites at the end of
reads.
1.2 Methods
1.2.1 Genomic DNA used to generate restriction enzyme exome libraries
NA19240 genomic DNA was purchased from Coriel DNA depository.
NA19240 Illumina exonic sequencing data and variant file was downloaded from
Complete Genomics database.
1.2.2 Restriction enzyme generated TruSeq DNA sample preparation
1.2.2.1 Restriction Digestion
Each restriction enzyme generated TruSeq DNA sample had the starting concentration
of 1.5 µg of genomic DNA. Each restriction enzyme digestion reaction was performed
with 1 unit of enzyme per 1µg of DNA. The enzymatic incubation time for each sample
was
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1 hour. For enzymes MluC1 (NEB), Alu1 (NEB) and HypCH4V (NEB), 5µl of 10X Buffer
4 (NEB), 1.25µl of enzyme (1000u/ml) and 43µl ddH20 was added to 1.25µl of gDNA
(1µg/µl) and incubated at 37˚C for 1 hour. For enzyme Fat1 (NEB), 5µl of 10X Buffer 2
(NEB), 1.25µl of Enzyme (1000u/ml) and 43µl H20 was added to 1.25µl of genomic DNA
(1µg/µl) and incubated at 55˚C for 1 hour. Immediately after digestion, all reactions were
cleaned using the QIAquick Nucleotide Removal Kit (QIAGEN) and eluted with 50µl
ddH20 with an expected 90% retention (~4.5µg).
1.2.2.2 Blunting and phosphorylating the gDNA
To repair the 3’ recessed ends made by the enzymes MluC1 and Fat1 and to
phosphorylate the 5’ end, 10µl of phosphorylation reaction buffer 10X (NEB), 5µl of T4
DNA polymerase (3u/µl, NEB), 5µl of T4 polynucleotide kinase (10u/µl, NEB), 4µl of
dNTPs (10mM), and 40µl of H20 was added to 50µl of fragmented DNA (0.9µg/ml) and
incubated at 20˚C for 30 minutes. Immediately after blunting and phosphorylating, all
reactions were cleaned using the QIAquick Nucleotide Removal Kit (QIAGEN) and
eluted with 32µ ddH20 with expected 80% retention (~3.6µg).
1.2.2.3 Adenylate of the 3’ end of the blunt DNA fragments
12.5µl of A-Tailing Mix (Ilumina) was added to 15µl of repaired DNA (67ng/µl) and
incubated for 30 minutes at 37˚C.
1.2.2.4 Ligating the Adaptors
2.5µl of DNA Ligase Mix (Ilumina) and 2.5µl of DNA Adapter (Ilumina) was added to the
27.5µl of DNA with A-Tails (above) and incubated for 10 minutes at 30˚C. DNA adapter
index 4 (Ilumina) was ligated to the library construct with Alu1. DNA adapter index 5
(Ilumina) was ligated to the library constructed with HypCH4V. DNA adapter index 2
(Ilumina) was ligated to the library constructed with Mlu1. DNA adapter index 7 (Ilumina)
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was ligated to the library constructed with Fat1. After incubation, 5µl of Stop Ligase Mix
(Ilumina) was added. The DNA library was then cleaned up twice with AMPure XP
Beads and resuspended in 22.5µl of Resuspension Buffer (Ilumina).
1.2.2.5 Library Enrichment
5µl of Primer Cocktail (Ilumina) and 25µl of PCR Master Mix (Ilumina) was then added to
1µg of ligated DNA. The library was then amplified on a thermal cycler with the following
conditions: 98˚C for 30 seconds, 10 cycles of (98˚C for 10 seconds, 60˚C for 30 seconds
and 72˚C for 30 seconds), 72˚C for 5 minutes and hold at 4˚C. The reaction was then
purified with AMPure XP Beads and re-suspended in 32.5µl of Resuspension Buffer
(Ilumina).
1.2.2.6 Exome Enrichment
Enrichment of the restriction enzyme library exome was performed following the
standard Illumina protocol “TruSeq Enrichment Guide”. The TruSeq Exome Enrichment
kit targets 62 million bases. The restriction enzyme generated TruSeq exome enriched
DNA sample were sequenced at 100 bp pair-end reads in one flow cell in an Illumina
sequencer HiSeq 2000. The subsequent sequences were processed by the standard
Illumina sequence quality-control pipeline.
Exome sequences were mapped to the human genome reference sequence hg19 by
BWA using the default parameters in paired mode

12

converted

were

to

BAM

files

and

duplicates

. The resulting SAM files were
removed

using

Picard

(http://picard.sourceforge.net). The mapped reads were locally realigned using GATK
RealignerTargetCreator 13 . Finally the variants were called with GATK following GATK
best practice protocol (Figure 5). To call phased data GATK, ‘ReadBackedPhasing’ was
used 13 .
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Figure 5. GATK best practice flow cart (http://gatkforums.broadinstitute.org/).
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1.3 Results
1.3.1 Mapping sequenced reads
The restriction enzymes (MluC1, Alu1, HypCH4V and Fat1) were chosen based on the
average genomic digest fragment length of the restriction enzyme (Table 1). These four
restriction enzyme generated exome NGS libraries were pooled and sequenced together
and reached 109X coverage and covered 87% of the 62 million TruSeq targeted
sequences (Table 2). Next, we analyzed if pooling different combinations of restriction
enzyme libraries would increase the percentage of the exome covered (Figure 6). By
combining four different restriction enzyme libraries, we are able to nearly double the
amount of exome covered in comparison to an exome covered by a single restriction
enzyme library (46% to 86%). While the exome NGS library generated by sonication
reached 20X coverage, it only covered 76% of the 62 million TruSeq targeted
sequences.
Interestingly, ~10% of the reads from the restriction enzyme libraries were unable to be
mapped to the human reference genome hg19. This is likely a result of either the library
reads length being outside of Illumina sequencing technology specifications or reads
being too short to align specifically to the reference genome. Reads that did not include
a restriction enzyme sequence at the start of the sequenced read (0.7% of the reads)
were removed from the data set.
Next, we compared the average paired end fragment length from the restriction enzyme
libraries to the fragment length generation by sonication. While the average read length
is comparable between the two libraries (174nt for restriction enzymes, 179nt for
sonication) the restriction enzyme libraries standard deviation was much greater than the
sonication library (174 ±120nt and 179 ±59nt, respectively).
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Table 2. Summary of restriction enzyme exome library sequenced with Illumina HiSeq 2000 100bp pair-end
reads
Restriction
enzyme
library

MluC1

Alu1

HypCH4V

Fat1

All four
enzymes

1000
Genome
(sonication)

Reads
%

35,514,484
100

54,521,560
100

44,955,256
100

49,058,158
100

184,049,458
100

32,740,442
100

4,714,350

6,354,982

4,519,560

4,358,828

19,947,720

188,494

13

12

10

9

11

1

30,800,134

48,166,578

40,435,696

44,699,330

164,101,738

32,551,948

87

88

90

91

89

99

320,751

4,116,781

2,726,051

1,205,967

8,369,550

-

1

8

7

3

5

-

266,300

35,148

232,294

622,713

1,156,455

-

.8

.08

.06

1

.7

-

30,213,083

43,694,649

37,477,351

42,870,650

154,255,733

32,551,948

85

80

83

87

84

100

30,213,083

43,694,649

37,477,351

42,870,650

154,255,733

32,551,948

100

100

100

100

100

100

16,696,935

22,455,881

20,099,998

22,960,533

82,213,347

16,815,776

55

51

54

54

53

52

nt mapped to
exome

1,381,746,304

1,858,148,710

1,665,029,685

1,884,831,045

6,789,755,744

1,221,211,997

X coverage
to exome

22

30

27

30

109

20

% exome
covered

45.14

50.71

45.14

41.98

86.53

76.05

Unmapped
reads
%
Mapped
reads
%
Paired reads
mapped
alternatively
%
Reads
without
restriction
sites
%
High quality
mapped
reads
%
High quality
mapped
reads
%
Reads
mapped to
exome
%
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Figure 6.

Pooling restriction enzyme libraries increases the percent of exome

nucleotides covered. After pooling the four restriction enzyme libraries, the percentage
of covered exome doubled from 46% to 86%.
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1.3.2 GATK called variants
After the poor quality reads (paired reads that mapped alternatively or reads without
restriction enzyme ends) were removed from both the restriction enzyme libraries and
sonication library data, the variant caller GATK was used to call variants from both data
sets.

To compare specificity and sensitivity of the variant calling between the two

datasets, the amount of overlapping variants between the two datasets with the
published variant list from Complete Genomics was analyzed. The Complete Genomic
variant list was compiled from multiple sequencing runs of the NA19240 genome and is
considered a highly accurate variant list. The restriction enzyme libraries showed higher
sensitivity to call variants (172,571 variants) in comparison to the sonication library
(79,330 variants). However, this high sensitivity to call variants in restriction enzyme
libraries was accompanied with a low specificity. 49% of the variants from the restriction
enzyme libraries overlapped with the Complete Genomic variant list compared to 97% of
the sonication library variants overlapped (Table 3). This high error rate might be due to
the inability of the restriction enzyme libraries to mark PCR amplified duplicate reads.
This is because PCR amplified reads are indistinguishable from multiple reads cut at the
same restriction enzyme site (Figure 7).
To increase the specificity of variant calling with the restriction enzyme libraries, only
variants that were covered by two different restriction enzyme library reads were called.
With this new constraint, the variants called from the sonication library had greater
sensitivity and specificity than the restriction enzyme library. 79,330 variants called
compared to 47,194 variants called, respectively.
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Table 3. Comparison of GATK called variants from restriction enzyme reads
and sonication reads
Variant
Overlapping with Complete
Called (%)
Genomics variants (%)
Variants called from both restriction
enzyme reads and sonication reads
Variants called from restriction
enzyme reads and not called from
sonication reads
Total number of variants from
restriction enzyme reads
Variants called from both sonication
reads and restriction enzyme reads
Variants called from sonication reads
and not called from restriction
enzyme reads
Total number of variants from
sonication reads

53,508 (31)

52,999 (99)

119,063 (69)

30,837 (26)

172,571 (100)

83,886 (49)

53,508 (67)

52,999 (99)

25,822 (33)

24,885 (94)

79,330 (100)

77,884 (98)
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A)#

B)#

Figure 7. Mapped reads generated by sonication and restriction enzymes.
A) Fragmenting the genomic DNA by sonication produces randomized fragments.
B) Restriction enzyme generated libraries produces non-randomized fragments that are
indistinguishable from PCR amplified reads.
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Furthermore, 98% of the sonication library variants overlapped with the Complete
Genomic variant list compared to 97% overlap with the restriction enzyme libraries
(Table 4).
1.3.3 Phasing variants
To compare the ability of sonication and restriction enzyme libraries to phase variants,
GATK ‘ReadBackedPhasing’ was used to call phased variants. To obtain an accurate
comparison, only variants that were called by both sonication and restriction enzyme
libraries (53,508 variants) were phased. The number of phased contigs were similar
between the two techniques (11,936 contigs in restriction enzyme library and 11,494
contigs in sonication library) (Table5). While the occurrence of contigs with two phased
variants are greater in the sonication library, the restriction enzyme libraries constantly
had a higher occurrence of contigs with >2 variants phased together than the sonication
library.
1.4 Discussion
In this project, I proposed a new method of genomic library construction.

It was

hypothesized that if random shearing of the genomic DNA was changed to precise
cutting of DNA with restriction enzymes, the variant error rate would decrease and the
amount of phased variants would increase because the library fragment size would be
more variable.
The results from this study showed both the benefits and problems with construction of
the genomic NGS library using restriction enzymes. The first problem is that there are
10-fold more unmapped reads than a library constructed by sonication.

These

unmapped reads are comprised of reads that are too small to be aligned to the reference
human genome.
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Table 4. Comparison of GATK called variants from ≥2 restriction enzyme library
reads and sonication reads
Overlapping with
Variant Called
Complete Genomics
(%)
variants (%)
Variants called from both ≥2 restriction
enzyme library reads and sonication
30,644 (65)
30,464 (99)
reads
Variants called from ≥2 restriction
enzyme library reads and not called from
sonication reads
Total number of variants from ≥2
restriction enzyme library reads
Variants called from both sonication and
≥2 restriction enzyme library reads
Variants called from sonication reads
and not called from ≥2 restriction
enzyme library reads
Total number of variants from sonication
reads

16,550 (35)

15,462 (93)

47,194 (100)

45,926 (97)

30,644 (39)

30,464 (99)

48,593 (61)

47,432 (98)

79,237 (100)

77,884 (98)
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Table 5. Phased variants per contig from restriction enzyme and sonication
libraries
Number of contigs
Number of phased
variants per contig
Restriction enzyme library
Sonication library
2
5,538
6,503
3
2,815
2,593
4
1,433
1,114
5
788
554
6
476
272
7
292
161
8
181
98
9
109
62
10
97
45
11
55
28
12
41
19
13
26
14
14
18
10
15
12
6
16
12
3
17
7
4
18
11
3
19
12
2
20
4
0
21
3
2
22
2
0
23
1
1
24
0
0
25
0
0
26
0
0
27
1
0
28
1
0
29
0
0
30
0
0
31
0
0
32
1
0
Total contigs
11,936
11,494
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Applying strict read size selection to the methodology of restriction enzyme library
construction may help correct this result.
While low quality reads lacking in restriction sequence ends could be filtered out with this
new method, the inability to distinguish between PCR duplicate reads and non-PRC
duplicate reads with the restriction enzyme libraries lead to a greater variant calling error
rate in comparison to the NGS library generated by the sonication of genomic DNA.
Because of this limitation, it was decided that only variants that were found in
overlapping restriction enzyme libraries should be called. While this filter decreased the
variant calling error rate of the restriction enzyme dataset, libraries generated by
sonication could still call variants with more specificity and sensitivity in comparison to
the restriction enzyme libraries.
Finally, we compared the ability of the two differently generated NGS libraries to call
phased variants. While the total number of contigs with phased variant were similar
between the restriction enzyme library and sonication library, the number of contigs with
>2 variants phased was consistently more in the restriction enzyme library.

This

observation is most likely due to the increased standard deviation read length in the
restriction enzyme library, 174±120 nt) for restriction enzyme and 179±59 nt) for
sonication.

	
  

31

CHAPTER 2. Identification and characterization of genetic modifiers of breast
cancer risk in BRCA1 mutation carriers
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2.1 Introduction
Breast cancer cases can be separated into two broad categories, sporadic cases and
cases with germline mutations.
cancer cases

11

.

Sporadic breast cancer make up 90% of all breast

The remaining 10% have some type of germline mutations that

predisposes the carrier for the development of breast cancer 14-17 . There are many
known germline genes that increase the risk of developing breast cancer 8,10,18-21 . One
of the most common breast cancer germline mutations, which affects about 10% of all
germline mutation carriers, are mutations in the gene BRCA1 10 (Figure 3).
2.1.2 BRCA1
BRCA1 (breast cancer 1, early onset) is a well-known tumor suppressor implicated in a
diverse array of biological processes, including DNA break repair, cell-cycle checkpoint
activation, transcription regulation and DNA replication

22-31

.

BRCA1 is located on

chromosome 17 and is comprised of 24 exons spanning 81,188 bp. BRCA1 mutation
carriers from familial breast cancer families have a 44-75% risk of developing breast
cancer by age 70 15 . This wide range of risk is due to different risk modifying factors.
These factors include specificity of the BRCA1 germline mutation, environmental
modifiers, and genetic modifiers 16,17,21,32-38 .
2.1.3 Genetic modifiers of breast cancer risk
Genetic modifiers of cancer risk has been hypothesized for over 20 years. In the mid1990s, cancer risk modifying alleles were first described in mice cancer models 39-41 .
While there have been many large genome wide association studies (GWAS) that
associated germline variants with a change of risk of breast cancer in BRCA1 germline
mutation carriers, there have been no follow up functional studies providing evidence
that these variants are actually the risk modifiers 42-45 (Table 6). There are a number of
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reasons why these variants have not been analyzed further. The main reason is the
inability to distinguish whether the identified variants are merely linked to the risk
modification or if the variant itself is the cause of change of breast cancer risk. Many of
the BRCA1 risk modifier GWAS studies used a 610k array SNP chip to genotype the
BRCA1 mutations carriers, of which 95% of the variants were from intronic or intergenic
regions of the genome (Figure 8). While intronic and intergenic regions are no longer
considered “junk DNA”, the functional consequence of variants in these regions is
difficult to predict.
2.1.4 Intervention options of BRCA1 mutation carriers
Currently, there are limited risk assessments and availability in options for the
intervention of breast cancer in high-risk women, leading some carriers to undergo an
invasive mastectomy.

Identifying germline modifiers can both provide better

personalized cancer risk assessments to BRCA1 mutation carriers and can potentially
lead to new therapies that may lower the risk for these carriers.
2.1.5 Benefits of NGS analysis
To identify variants that have a functional possibility of modifying the risk of developing
breast cancer in BRCA1 carriers, we used NGS to sequence the exome of 54 BRCA1
mutation carriers.

Using NGS will increase sensitivity for variant detection in

comparison to an array SNP chip. This increase in sensitivity will allow the usage of
biological filters, which will increase the likelihood of finding functional risk modifying
variants. The first biological filter used in this study will be variant function prediction
software. All variants that are predicted to be non-damaging to the function of the gene
will be filtered out as their influence on the affected gene are less predictable.

	
  

34
Table 6. Summary of published genetic modifiers of breast cancer risk in BRCA1 mutation carriers
SNPs

GENE

Molecular
consequence

Affected

Unaffected

HR

MAF

P

rs4808611

NR2F6

intronic

4144

3362

1.27

0.102

1.6

-10

42

rs8100241

ANKLE1

exonic (SIFT
Damaging)

4151

3368

0.89

0.46

1.6

-10

42

rs2363956

ANKLE1

exonic (SIFT
Damaging)

4150

3367

0.84

0.46

2.4

-10

42

intergenic

5301

3699

1.16

0.17

4.5

-10

43

rs67397200

ANKLE1,
ABHD8

Ref

rs8170

BABAM1

synonymous

5890

4380

1.23

0.11

2.1

-9

43

rs3745185

BABAM1

intronic

4152

3369

0.86

0.31

7.1

-8

42

rs6138178

SNRPB

intronic

3451

0.78

0.428

0.0015

rs6602595

CAMK1D

intronic

3451

1.25

0.481

0.0019

rs1048635

TRIM45

UTR3

3451

1.5

0.06

0.0029

1.18

0.147

0.005

1.26

0.247

0.0056

rs13387042

TNP1,

intergenic

4763

4268

45
45
45
44

Function

-

-

-

-

-

-

-

DIRC3
rs6590224

KIRREL3

HR, Hazard Ratio
MAF, Minor allele frequency
Ref, References

intronic

3451

45

-
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610K array SNP distribution
Codon/
splicing
SNPs*
1%

Other
SNPs**
4%

Intronic
and
intergenic
SNPs
95%

*nonsynonymous, stopgain, stoploss and splicing
**synonymous, upstream, downstream, non-coding and UTRs
Figure 8. Distribution of variants on the 610k array. A large percentage of SNPs
analyzed on the 610k array are in intronic and intragenic regions.
consequence of SNPs in these regions of the genome are difficult to decipher.

Molecular
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To further increase the likelihood of selecting a functionally relevant variant, a PubMed
literature search will be used to select only variants that occur in genes that have
predicted roles in cancer. It is important to note that genes with unknown functions and
variants that have no effect on the translated amino acid may, in fact, affect BRCA1
mutation carrier breast cancer risk.

However, because this study will analyze the

functional consequence of these variants using in vitro assays, strict filters will be used
to increase the likelihood of accomplishing this goal.
2.2 Materials and Methods
2.2.1 Statistical association study
2.2.1.1 Samples used in the case control study
The samples used in this study are from Creighton University Breast Cancer Family
Registry. Participants provided written informed consent for cancer genetic study.
Institutional Review Board of Creighton University and Institutional Review Board
University of Nebraska Medical Center approved the study (CU #00-12265, UNMC
#718-11-EP).
The cases included 27 BRCA1 mutated carriers that were diagnosed with breast cancer.
All breast cancer affected cases were matched with a control breast cancer unaffected
individual that shared the same BRCA1 mutation from the same family.

If multiple

breast cancer affected carriers were available, the individual diagnosed at the earliest
age was selected. If multiple unaffected carriers were available, the oldest individual
was selected. In total there were 27 cases and 27 controls from 27 families.
2.2.1.2 Samples used in the cohort study
The BRCA1 mutated carrier sample size was increased from 54 BRCA1 mutation
carriers in the case control study to 161 BRCA1 mutation carriers in the cohort study.
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These 107 new BRCA1 mutation cases were only selected based on the BRCA1
mutation status.
2.2.1.3 Statistical association of genetic modifiers to breast cancer risk
Odds ratio (OR) and their 95% confidence intervals (CI) were estimated using the
unconditional maximum likelihood with the R package Epitools software. The variants
that passed the biological filters and odds ratio statistics were then re-analyzed in a
cohort study using the Cox regression model 46 . The Hazard Ratio (HR), their 95%
confidence interval (CI) and Wald’s P-value were calculated using the R package
Survival software.
2.2.1.4 Illumina Exome libraries preparation
DNA from blood cells was extracted from the selected BRCA1 mutation carriers by Dr.
Lynch’s laboratory and was shipped to Dr. San Ming Wang’s lab for analysis.

The

exome libraries were prepared and captured by using the SureSelectXT2 Target
Enrichment System (Agilent Technologies, which has a total amount of targeted
sequence of 75 million bases. The libraries were sequenced in an Illumina sequencing
platform HiSeq 2500 with 150bp paired-end reads with the goal of 50X coverage, based
on nucleotides mapped to the exome.
2.2.1.5 Mapping, variant calling and damaging prediction
After samples were sequenced, the last 25% of each read was trimmed with fastqxtrimmer 47 before being mapped to the human reference genome hg19 by the program
BWA

48

.

Once mapped, the reads were locally realigned and the duplicates were

marked with Picard

49

.

The variants were then called with the program

GATK_HaplotypeCaller following GATK best practice protocol 50 (Figure 5). All of the
variants were analyzed with the program AnnoVar 51 . The computer software PolyPhen2
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and Sift was used to determine if the change in amino acid would likely be damaging to
the function of the protein 52,53 .
2.2.1.6 PCR products Sanger sequenced
The 5’ and 3’ oligonucleotide primers were manually designed for each DNA sequenced
and were ordered from IDT. To genotype the BRCA1 mutation carriers, the following
primers were used.
SYNE1_ rs2295190
F 5’- TTGCTTATGACCCGATCCTC-3’
R 5’- GAAGGTGCAGAGGCAAAAAG-3’
ANKLE1_ rs8100241
F 5’- GAGACGCTGGACTCCATAGC-3’
R 5’- CAGCTCCAGAGACCTCAACC-3’
ANLN_rs3735400
F 5’- GCTGAAAGAGAATGGGGTTTT-3’
R 5’- GCAGATGTCGACTCAACTGG-3’
SIPA1L2_ rs1547742
F 5’- AAGAACAGCCAGCCACCTTA-3’
R 5’- CCTCAGTGGTTCTCACCATTC-3’
MTHFSD_ rs3751800
F 5’- CAGGGCTCTCTTCAGGTCAC-3’
R 5’- GCCTGGAGATGATGGAGAAA-3’
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PCR were carried out in a PTC-200 thermal cycler (MJ Research).

The following

components are added to the final PCR master mix: 15ng of DNA template, 0.1mM
dNTP mixture, 1X GoTaq buffer (Promega), 1µM primers (5’ and 3’), and 1u/µl GoTaq
(Promega). First, the template DNA was denatured at 95˚C for 7 minutes. Next, 38
cycles of 95˚C for 30sec, 57˚C for 30sec, 72˚C 45sec (depending on expected fragment
size, 1kb=45sec). The last PCR cycle was a final extension of 72˚C for 7 minutes.
Before the sequences are Sanger sequenced, the PCR products are cleaned with SAP
(1u/µg of DNA), 1X SAP buffer, and Exo1 (1u/µg of DNA). This reaction was incubated
at 37˚C for 60 minutes and denatured at 95˚C for 20 minutes before the primer is
premixed with the sample and sent for Sanger sequencing.
2.2.2 Functional Study
2.2.2.1 Bacterial strains
NEB 10-beta electrocompetent E. coli genotype: ∆(ara-leu)7697 araD139 fhuA ∆lacX74
galK16 galE15 e14- Φ80dlacZ∆M15 recA1 relA1 endA1 nupG rpsl (StrR)rph spoT1
∆(mrr-hsdRMS-mcrBC)
XL10-Gold ultracompetent E. coli genotype: TetR ∆(mcrA)183 ∆(mcrCB-hadSMR-mrr)
173 endA1 supE44 thi-1 recA1 gyrA96 relA1 lac Htee [F’ proAB laclqZ∆M15 Tn10 (TetR)
Amy CamR].
2.2.2.2 Bacterial Cell Growth Conditions
LB media was made with 10g NaCl, 10g tryptone, 5g yeast extract (per liter of media)
and pH to 7.0 with 5N NaOH. If solid media was required, 20g of agar per liter was
added before sterilization by autoclaving.

Once the sterilized LB media cooled,

depending on desired antibiotic selection, kanamycin (50µg/ml), ampicillin (100µg/ml), or
carbenicillin (100µg/ml) was added.
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E. coli cells inoculated in liquid LB media was grown in a C24 incubator shaker (New
Brunswick Scientific) at 37˚C, 200 rpm overnight. E. coli cells inoculated on solid LB
media was grown at 37˚C overnight.
2.2.2.3 Bacterial transformation
2.2.2.3.1 Electorcompetent transformation
1µl of DNA was added to E. coli beta-10 cells in a chilled 1mm electroporation cuvette
(Bioexpress) and mixed by flicking gently.

Cells were shocked with the Bio-Rad

micropulser at 2.0 kv, 200Ω, and 25µF, 975µl pre-warmed (37˚C) SOC outgrowth
medium was transferred to the cuvette and then transferred to a culture tube. The cells
were then shaken vigorously (250 rpm) at 37˚C for 1h, then spread onto four prewarmed LB selection plates and incubated overnight at 37˚C.
2.2.2.3.2 Chemical competent transformation
45µl of XL10-Gold cells was added to a pre-chilled 14-ml polypropylene tube, 2µl of βmercaptoethanol was added. Cells were incubated on ice and swirled gently every 2
minutes for 10 minutes, then 2µl of DNA was added to the ultracompetent cells. After
the cells were incubated on ice for 30 minutes, the cells were heat-pulsed in a 42˚C
water bath for 30s. The heat-pulsed cells were then incubated on ice for two minutes
before 0.5ml of preheated (42˚C) SOC media was added. These cells were incubated at
37˚C for one hour at 250 rpm before the cells are spread onto four pre-warmed LB
selection plates and incubated overnight at 37˚C. Plasmid DNA was purified with the
QIAprep Spin Miniprep Kit (QIAGEN).
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2.2.2.4 Mammalian Cell line Growth Conditions
HCC1937 cell line was grown at 37˚C, 5% CO2 atmosphere in Roswell Park Memorial
Institute medium (RPMI 1640, ATCC) supplemented with 10% FBS (Gibco), and 1X
streptomycin/penicillin (Gibco).
HEK 293T cell line was grown at 37˚C, 5% CO2 atmosphere in Dulbecco’s Modified
Eagle

Medium

(DMEM,

ATCC)

supplemented

with

10%

FBS,

and

1X

streptomycin/penicillin.
HeLa cell line was grown at 37˚C, 5% CO2 atmosphere in Dulbecco’s Modified Eagle
Medium (DMEM, HyClone) supplemented with 10% FBS, and 1X streptomycin/penicillin.
MCF7 cell line was grown at 37˚C, 5% CO2 atmosphere in Eagle’s Minimum Essential
Medium (EMEM, ATCC) supplemented with 10ug/ml insulin from bovine pancreas, 10%
FBS, and 1X streptomycin/penicillin.
2.2.2.5 shRNA stable cell line production
E. coli LX10 gold carrying packaging plasmid psPAX2, envelope plasmid pMD2.G, and
scramble shRNA (on the vector backbone pLKO.1) were purchased from Addgene.
ANLN shRNA (TRCN0000117257) bacterial glycerol stock were purchased from SigmaAldrich.
2.2.2.6 Lentiviral particles production
To start the lentiviral particle packaging, 7×105 HEK-293T cells were plated on a 6 cm
tissue culture plate at 37˚C, 5% CO2 in DMEM +10% FBS without antibiotics overnight.
After 12-15 hours, a plasmid cocktail of 1µg pLKO.1, 750ng psPAX2, 250 ng pMD2.G
was added to 20µl of OPTI-MEM (Invitrogen).

Next 10µl of Lipofectamine 2000

(Invitorgen) was added to 90 µl of OPTI-MEM (Gibco) and incubated at room
temperature of 5 minutes. The lipofectamine 2000 master mix was then added to the
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plasmid cocktail and incubated for 20-30 minutes at room temperature. This mixture
was then added to the cells and incubated at 37˚C, 5% CO2 overnight. In the morning,
fresh media with antibiotics was added and the cells were incubated at 37˚C, 5% CO2 for
24 hours.

After 24 hours, the media was harvested and 5ml of fresh media containing

antibiotics was added to the cells and incubated at 37˚C, 5% CO2 for 24 hours. Again,
after 24 hours, the cells were harvested. The harvested media was then filtered through
a

0.45µm

filter

and

stored

at

-20˚C.

SYNE1

shRNA

infection

particles

(TRCN0000147281) were purchased from Sigma-Aldrich.
2.2.2.7 Infecting Target Cells
Target cells were plated at 50% confluence at 37˚C, 5% CO2 overnight.

The next

morning, fresh culture media containing 8µg/ml polybrene (Santa Cruz) was added.
Next, 0.5ml of lentiviral particles was added to the target cells and incubated at 37˚C, 5%
CO2 for 24 hours.

The media was then changed after 24 hours.

Two days after

infection, stable cell lines were selected using 1µg/ml of puromycin (Sigma-Aldrich).
2.2.2.8 DNA Transfection Procedure
Target cells were plated in a 6-well plate in growth medium without antibiotics at 37˚C,
5% CO2 for 24 hours. Once the cells were 90% confluent, 4.0µg of DNA was diluted in
250µl of Opti-MEM and 10µl of Lipofectamine 2000 diluted in 250µl of Opti-MEM. After
5 minutes of incubation at room temperature, the diluted DNA was combined with the
diluted Lipofectamine 2000 and incubated for 20 minutes at room temperature. The
complexes were added to the cells and medium and mixed by gently rocking the plate
back and fourth. Cells were grown for 48 hours before imaging or selective medium was
added.
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2.2.2.9 Growth curve
Stable shRNA cells were seeded at 3.0×104 in 6-well plates with complete EMEM media
without antibiotics. The seeded cells were allowed to grow for 24 hours before the first
time point was collected. The following time points were collected every 24 hours for
five more days. Cell viability was determined with 0.04% trypan blue (Gibco). Cells
were counted manually with a hemocytometer (Bright-Line).
2.2.2.10 Microscopy
Two days after transient transfection, cells were transferred and grown on a glass
coverslip for 24 hours. Cells were then fixed with 4% paraformaldehyde in PBS. DAPI
Fluoromount-G was used to mount and stain the nucleus. These cells were then imaged
on a Nikon Eclipse TI-E microscope with a Nikon Digital sight DS-QiMc camera. Images
were overlaid in NIS Elements (Nikon) and fluorescence intensity were measured with
the software ImageJ.
2.2.2.11 Western Blot
To extract whole cell lysate from living cells, a lysing buffer (5% glycerol, 1.5% SDS) was
added directly to the cells. Proteins were then denatured at 95˚C for 10 minutes and
protein concentrations were measured using a BCA protein assay Kit (Pierce) on an
iMark microplate absorbance reader (Bio Rad).
Proteins were separated by SDS-PAGE and transferred to nitrocellulose membrane
(Immobilon-P) for subsequent blotting with antibodies. Both SYNE1 and ANLN proteins
were separated by a 9% SDS-PAGE gel. To blot for ANLN, a monoclonal anti-ANLN
AMAB90660 antibody produced in mouse was used (Sigma-Aldrich) while SYNE1 was
probed using a monoclonal anti-SYNE1 SAB1404967 antibody produced in mouse
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(Sigma-Aldrich). To blot Hsc70, a monoclonal anti-Hsc70 ab19136 antibody produced in
mouse was used (abcam). The secondary antibody used for all western blot assays was
anti-mouse IgG, HRP-linked antibody 7076s (Cell Signaling Technology). All blots were
developed on Blue Lite Autorad Film (GeneMate).
2.2.2.12 ANLN construct design and verification
Overexpressing eGFP-anillin vector was a gift from Dr. Andrew Wilde’s lab

54

. The

variant was induced with overlapping oligonucleotides with the QuickChange 2 XL SiteDirected Mutagenesis Kit (Agilent Technologies).
Oligonucleotides used to induce the variant in the ANLN_rs3735400 construct:
F 5’- gagaaatcttgtacaaaaccatGgccatcaaaaaaacgctg-3’
R 5’-cagcgtttttttgatggcCatggttttgtacaagatttctc-3’.
To verify the induced variant, the vector was Sanger sequenced with primer:
5’-CTGCACCTGAGGAGACACAG-3’.
To generate the eGFP vector without anillin, the following primers were used to amplify
only the vector backbone.
F 5’- aatggatccgtttacggagaaactgc -3’
R 5’- ctacaaacctattggaaagccttaa -3’
After the vector backbone was made, DpnI endonuclease (10 U/µl) was incubated with
the PCR product at 37˚C for 1 hour to digest the plasmid construct. To add 5’ phosphate
to the DNA sequence, T4 polynucleotide kinase (NEB) (10U/µl) with 1x T4 ligase buffer
was incubated at 37˚C for 1 hour. To ligase the DNA sequence, T4 DNA ligase (NEB)
(1U/µl) was incubated with the DNA sequence at room temperature for 2 hours.
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2.2.2.13 SYNE1 construct design and verification
EGFP-C2_DN-Nesprin-1 vector was a gift from Dr. Angelika Noegel’s lab

55

.

The

variant was induced with overlapping oligonucleotides with the QuickChange 2 XL SiteDirected Mutagenesis Kit (Agilent Technologies).
Oligonucleotides used to induce variant in the SYNE1_rs2295190 construct:
F 5’-gtgggtcgagccttcAtgttccggatcctc-3’
R 5’-gaggatccggaacaTgaaggctcgacccac-3’
To verify the induced variant, the vector was Sanger sequenced with primer:
5’-TGTGAGTCCCACATCCGGAA-3’
2.3 Results
2.3.1 Statistical association study
2.3.1.1 BRCA1 mutated carriers sample selection
To increase the chance of identifying variants that modify the risk of developing breast
cancer in BRCA1 mutation carriers, we set strict criteria for sample selection. All of the
BRCA1 mutation carriers’ mutations must be listed in breast cancer information core
(BIC) database as clinically important and/or large deletions of BRCA1 must have been
identified. Because the specificity of the BRCA1 mutation has been shown to modify the
risk of breast cancer, the breast cancer affected and unaffected mutation carriers were
matched by the specificity of their mutation 32-34 . Furthermore, because age is a strong
risk factor for breast cancer development, the affected and unaffected individuals were
also matched by at least 5 years 16 . To increase the likelihood of identifying variants
that increase the risk of developing breast cancer, the youngest breast cancer affected
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case was selected if multiple cases were available. Likewise, to increase the chance of
identifying variants that decreased the risk of developing breast cancer, the oldest breast
and ovarian cancer unaffected BRCA1 mutation carrier was selected if multiple cases
were available. There were 27 BRCA1 mutated carriers that were diagnosed with breast
cancer and 27 BRCA1 mutated carriers unaffected by breast cancer from 27 families
that matched all selection criteria (Table 7).
2.3.1.2 NGS mapping, variant calling and variant annotation
All 54 genomes were then processed into 54 NGS exome libraries using the
SureselectXT2 exome+UTR capture kit. This capture kit was designed to capture 75
million nucleotides per genome. The libraries were sequenced on the Illumina HiSeq
2500 at 150bp pair-end reads with 2.67 libraries seeded per lane. After the 54 samples
were sequenced, the average depth of sequenced reads in the exome was 66.5 (66.5X
coverage) (Table 8). The 54 samples also had, on average, 97.5 percent of the 75
million nucleotides captured. While GATK called, on average, over 1 million variants per
sample, the 54 samples had on average 2,105 variants predicted damaging by
PolyPhen2 or SIFT per genome (Table 9).
2.3.1.3 Case control study to identify candidate genetic modifiers
2.3.1.3.1 Previously identified breast and/or risk modifying variants
CIMBA and other laboratories have previously published genetic variants that
statistically modify the risk of breast and ovarian cancer

17,21,37,56,57

studies extracted genomic data through the use of SNP arrays.
significantly less expensive than NGS.

. Most of these
These arrays are

This method of genotyping allowed these

laboratories to genotype many thousands of samples per analysis.
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Table 7. Breast cancer cases and controls selected for the case control study
Samples
in
families

Ethnicity

1

Polish

2

Irish

3

Ashkenazi
Jewish

4
5
6
7
8
9
10

BIC
clinically
importance

Sex

BC
diag
age

Current
age of
affected

Current
age of
unaffected

Coefficient of
relationship

-

F

31

56

57

1.56

yes

F

35

57

62

50

185delAG-ter39

yes

F

37

64

56

25

Asian

185delAG-ter39

yes

F

38

71

61

0.195

German/
Irish/
Swiss/
English/
French/
Norwegian

185delAG-ter39

yes

F

36

56

57

12.5

English/Irish

188del11-ter36

yes

F

31

58

71

6.25

English/Irish/
Scottish

254-1G-Texon5
2841Glu-ter (GT)
300Cys-Gly (TG)

yes

F

22

68

58

50

yes

F

27

50

56

50

yes

F

28

70

65

12.5

yes

F

35

75

78

6.25

yes

F

38

69

64

50

yes

F

33

72

63

3.125

yes

F

32

61

62

3.125

yes

F

44

82

49

50

yes

F

32

60

61

50

yes

F

35

56

54

50

yes

F

24

56

58

3.125

-

F

36

72

80

12.5

yes

F

38

56

69

25

yes

F

59

64

59

12.5

yes

F

29

60

56

12.5

yes

F

27

64

73

25

Irish
Dutch/
Indian
Choctaw
Indian/Irish/
French

BRCA1 Mutation

1008 bp delexon 17
1623del5ter503

332-11TGins59-ter75

Russian/
Jewish
Ashkenazi
Jewish

5272-2delAexon 19
5382insCter1829
5382insCter1829
5382insCter1829

15

Unknown

5622Arg-terC-T

16

German/
English

17

Irish/French

18

Caucasian

19

German

20

Caucasian

21

Scandinavian

882Glu-ter (GT)
916delTTter285
del37kb (exons
1-2)
Exon 11
1240delC
Exon 11
3829delTT
Exon 11
4184del4
(TCAA)
Exon 16
C4808G

11

Scandinavian

12

Caucasian

13
14

22
23

Czech/
German
German/
English

Glu143ter

yes

F

28

56

53

50

yes

F

44

72

69

6.25

24

Irish/Dutch

ins6kbEx13ter1460

25

Irish/Scottish/
English/
German

ins6kbEx13ter1460

yes

F

39

61

58

50

26

Dutch/German

IVS121632del3835

yes

F

29

51

74

1.56

27

German/
Polish

IVS6-2delA

yes

F

34

56

58

50

34

63

62

25

Average
BIC, breast cancer information core
BC diag, breast cancer diagnosed
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Table 8. Breast cancer cases and controls sequenced with Illumina HiSeq 2500
150bp pair-end reads	
  
Samples	
  
in	
  
families	
  

	
  

Affected	
  

Unaffected	
  

Reads	
  aligned	
  to	
  
Exome+UTR	
  

Affected	
  

Unaffected	
  

Affected	
  

nt	
  mapped	
  to	
  Exome+UTR	
  

Unaffected	
  

X	
  coverage	
  

Affected	
  

Unaffected	
  

%	
  of	
  covered	
  nt	
  in	
  
Exome+UTR	
  

1	
  

86,482,134	
  

56,073,196	
  

7,650,127,187	
  

5,081,972,608	
  

103	
  

68	
  

99.8	
  

99.7	
  

2	
  

69,068,541	
  

48,956,004	
  

6,394,426,226	
  

4,522,927,280	
  

86	
  

61	
  

99.1	
  

99	
  

3	
  

47,886,957	
  

77,915,392	
  

4,441,973,829	
  

7,135,423,515	
  

60	
  

96	
  

97.6	
  

99.1	
  

4	
  

21,985,934	
  

13,626,780	
  

2,074,862,383	
  

1,276,001,973	
  

38	
  

17	
  

93.6	
  

91.8	
  

5	
  

55,116,882	
  

47,775,867	
  

5,098,710,336	
  

4,436,831,644	
  

68	
  

59	
  

99.2	
  

99	
  

6	
  

55,166,279	
  

79,944,830	
  

5,066,027,968	
  

7,361,958,066	
  

68	
  

99	
  

99.3	
  

98.6	
  

7	
  

60,172,743	
  

80,817,890	
  

5,508,038,601	
  

7,437,637,846	
  

74	
  

100	
  

99.3	
  

99.5	
  

8	
  

37,734,040	
  

59,774,690	
  

3,543,666,305	
  

5,464,037,573	
  

48	
  

73	
  

98.6	
  

99.5	
  

9	
  

18,011,958	
  

18,187,259	
  

1,614,674,303	
  

1,640,546,264	
  

22	
  

22	
  

99	
  

99	
  

10	
  

72,771,441	
  

84,314,028	
  

6,689,109,600	
  

7,764,194,016	
  

90	
  

104	
  

99.2	
  

99.5	
  

11	
  

66,480,847	
  

39,019,760	
  

6,146,505,581	
  

3,644,376,137	
  

82	
  

49	
  

98.9	
  

97.9	
  

12	
  

35,765,547	
  

54,349,173	
  

3,366,493,766	
  

5,039,766,988	
  

45	
  

68	
  

96.3	
  

98.1	
  

13	
  

56,547,996	
  

51,214,730	
  

5,267,931,073	
  

4,772,844,570	
  

71	
  

64	
  

98.7	
  

68.7	
  

14	
  

38,511,142	
  

56,675,359	
  

3,612,334,201	
  

5,341,321,374	
  

48	
  

72	
  

96.7	
  

96.8	
  

15	
  

54,378,902	
  

84,654,781	
  

4,886,131,853	
  

7,637,212,363	
  

66	
  

102	
  

99.7	
  

99.7	
  

16	
  

41,335,655	
  

62,937,605	
  

3,856,415,232	
  

5,840,077,590	
  

52	
  

78	
  

98.4	
  

98.8	
  

17	
  

12,612,972	
  

85,809,640	
  

1,146,953,942	
  

7,930,384,563	
  

15	
  

106	
  

95.6	
  

99	
  

18	
  

43,517,923	
  

58,476,261	
  

4,032,437,129	
  

5,418,436,409	
  

54	
  

73	
  

97.9	
  

98.6	
  

19	
  

69,286,743	
  

53,981,810	
  

6,408,976,368	
  

4,982,461,829	
  

86	
  

67	
  

99.2	
  

99.3	
  

20	
  

63,541,452	
  

46,826,633	
  

5,962,051,678	
  

4,376,285,715	
  

80	
  

59	
  

97.8	
  

97.3	
  

21	
  

57,691,353	
  

60,787,449	
  

5,322,148,179	
  

5,630,617,835	
  

71	
  

76	
  

98.9	
  

99	
  

22	
  

42,236,230	
  

70,764,096	
  

3,866,064,306	
  

6,456,266,070	
  

52	
  

87	
  

99.3	
  

99.5	
  

23	
  

27,344,435	
  

48,757,397	
  

2,462,470,795	
  

4,387,785,253	
  

33	
  

59	
  

99.3	
  

99.7	
  

24	
  

62,454,282	
  

61,252,680	
  

5,694,441,590	
  

5,602,955,013	
  

76	
  

75	
  

99.5	
  

99.4	
  

25	
  

24,193,171	
  

68,955,803	
  

2,262,053,398	
  

6,365,367,452	
  

30	
  

85	
  

95.6	
  

99.3	
  

26	
  

19,207,071	
  

48,099,604	
  

1,745,532,463	
  

4,492,557,879	
  

23	
  

60	
  

98.6	
  

98.5	
  

27	
  

76,433,608	
  

46,069,340	
  

7,086,838,681	
  

4,232,751,636	
  

95	
  

57	
  

99.4	
  

92.5	
  

Average	
  

48,738,379	
  

58,000,669	
  

4,489,162,851	
  

5,343,444,424	
  

61	
  

72	
  

98	
  

97	
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Table 9. Breast cancer cases and controls variants called with GATK and
analyzed with PolyPhen2 and SIFT
Samples in
families

Total Variants

Total Exonic Variants

Total Predicted Damaging
Variants

Affected

Unaffected

Affected

Unaffected

Affected

Unaffected

1

978,062

1,113,898

19,372

20,724

2,412

2,159

2

1,636,156

900,886

19,134

19,093

2,136

2,189

3

1,085,031

1,743,506

18,259

18,745

2,078

2,025

4

679,774

474,424

15,422

14,659

1,698

1,597

5

1,082,048

936,887

19,530

19,179

2,144

2,136

6

1,223,782

1,204,419

18,931

19,169

2,123

2,150

7

1,319,263

1,225,337

20,681

19,894

2,524

2,271

8

814,889

1,377,287

19,211

19,342

2,133

2,167

9

294,220

316,551

18,890

18,687

2,127

2,052

10

1,263,491

1,424,578

19,513

19,184

2,220

2,101

11

1,370,974

901,320

19,285

18,623

2,133

2,064

12

1,029,280

1,586,600

17,270

18,605

1,974

2,102

13

1,351,599

1,175,098

18,995

18,636

2,112

2,077

14

1,134,786

1,500,802

17,515

19,401

2,003

2,320

15

1,013,404

1,254,739

19,677

19,727

2,133

2,140

16

780,891

1,611,728

18,690

18,200

2,096

1,949

17

313,035

1,910,332

16,012

18,130

1,741

1,997

18

1,025,958

1,198,271

18,683

18,939

2,106

2,103

19

996,549

1,415,127

19,020

18,930

2,241

2,137

20

1,202,093

838,836

19,131

19,422

2,148

2,151

21

1,654,218

1,315,488

17,828

17,893

1,991

2,027

22

1,362,266

1,320,138

19,065

19,294

2,138

2,186

23

1,046,242

1,497,137

19,259

18,954

2,180

2,057

24

505,466

734,575

19,269

20,258

2,140

2,269

25

1,311,678

1,418,653

19,096

18,745

2,123

2,031

26

424,269

1,155,242

17,294

19,658

1,875

2,192

27

467,546

1,036,908

18,490

19,132

2,061

2,157

Average

1,359,857

962,818

19,609

19,067

2,189

2,085
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Because we are only analyzing the variants from 54 samples, we must first verify that we
have the sensitivity to call variants that are true positives. To do this, we first identified
variants previously published to change the risk of breast or ovarian cancer.
We hypothesized that if our sample size was large enough to identify previously
identified genetic risk modifiers, we would also be able to identify new genetic risk
modifiers.
To identify these previously identified variants, the Odds Ratio was calculated on the
variants predicted damaged by either PolyPhen2 or SIFT. Each variant that segregated
differently between the breast cancer affected and unaffected with the statistical
significance of P≤ 0.15 were analyzed further through a search in PubMed.

The

PubMed search found two variants previously identified to change the risk of breast or
ovarian cancer (Figure 9). The variant rs8100241 in ANKLE1 has been identified by
CIMBA to decrease the risk of breast cancer in BRCA1 mutation carriers

42,43,58,59

.

Similarly, this variant also segregates more in the unaffected samples in the case control
study. The variant rs2295190 in SYNE1 has been previously identified to increase the
risk of ovarian cancer

60

. Similarly, this variant also segregates more in the breast

cancer affected samples than in the case control. These results show that our case
control sample size of 54 is large enough to identify previously identified risk modifying
variants.
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Figure 9. Probable biological variants previously identified to associate with
breast or ovarian cancer risk. All variants that segregated with a p≤0.15 and predicted
damaging by PolyPhen2 (PP2) or SIFT were manually searched in PubMed to find
published association of the variant with breast or ovarian cancer.

The variant

rs8100241 in ANKLE1 was previously identified by CIMBA to decrease the risk of breast
cancer in BRCA1 mutation carriers.

The variant rs2295190 in SYNE1 has been

identified previously to increase the risk of ovarian cancer.
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2.3.1.3.2 Newly identified breast and/or risk modifying variants
Next, we attempted to identify new variants that modified the risk of breast cancer in
BRCA1 affected carriers. To decrease the chance of false positive variants, we set both
statistical and biological filters as follows:
1. The variants are predicted damaging by both PolyPhen2 and SIFT.
2. The variants segregate with the statistical significances of P<0.05.
3. Ingenuity pathway analysis link the affected gene to cancer
4. There is a publication in PubMed that gives evidence that the affected gene is a
known or a predicted tumor suppressor/oncogene.
5. The amino acid change is in a known functional domain or odds ratio is <0.05 or
>20 or the affected gene has a protein-protein interaction with a high-medium
penetrance breast cancer predisposition gene.
The variant ANLN_rs3735400, SIPA1L2_rs1547742 and MTHFSD_rs3751800 met all
five criteria 61-66 (Figure 10). These new and previously identified risk modifiers were
then verified with Sanger sequencing and the odds ratios per allele was calculated
(Table 10). After Sanger sequencing, all five variants passed all biological and statistical
filters.
2.3.1.4 Cohort study to calculate the cumulative risk of the candidate genetic
modifiers
I then calculated if these variants changed the cumulative risk of developing breast
cancer.

To answer this question, the five variants were analyzed further in a more

statistically robust cohort study.
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Figure 10. Probable biological variants newly identified to associate with breast
cancer risk.

All variants that segregated with a P<0.05 and predicted damaging by

PolyPhen2 (PP2) and SIFT were searched in both Ingenuity pathway analysis (IPA) and
PubMed for evidence that they affect known/predicted oncogene or tumor suppressors.
These variants must also 1) cause an amino acid change in a known functional domain,
2) have an odds ratio <0.05 or >20, or 3) the affected gene must have a protein-protein
interaction with a high-medium penetrance breast cancer predisposition gene.
The variants ANLN_rs3735400, SIPA1L2_rs1547742 and MTHFSD_rs3751800 passed
through all five filters.
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Table 10. Sanger sequenced risk modifying variants Odds Ratio per allele
BRCA1
BRCA1
AA
Functional
Affected Unaffected MAF*
change Domain
(%)
(%)

dbSNP

Gene

rs2295190

SYNE1

9 (16.7)

4 (7.4)

17.5

L-M

rs8100241 ANKLE1

17 (31.5)

31 (57.4)

45.5

2 (3.7)

11 (20.4)

rs1547742 SIPA1L2

0 (0)

rs3751800 MTHFSD

3 (5.6)

rs3735400

*HapMap-ceu

ANLN

OR

95% Cl

P

KASH

2.87

0.760-10.865

0.119

G-A

-

0.37

0.170-0.808

0.013

11.3

S-W

NLS

0.15

0.033-0.748

0.020

8 (14.8)

9.7

S-L

-

0.05

0.003-0.931

0.045

11(20.4)

10.1

R-C

-

0.24

0.063-0.917

0.037
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In this cohort study, ~150 BRCA1 mutation carriers (16 unaffected and 80-91 breast
cancer affected), were genotyped by Sanger sequencing and the Cox regression model
was used to calculate the cumulative risk. These new BRCA1 mutation carriers were
selected based on the BRCA1 mutated status.
After the cumulative risks were calculated, it was shown that all five variants statistically
modify the risk of breast cancer in these BRCA1 mutation carriers. SYNE1_rs2295190
was the only variant to increase the risk of developing breast cancer in BRCA1 mutation
carriers (HR 1.66, CI 1.05-2.63, P=0.031) (Figure 11). ANKLE1_rs8100241, which was
shown to decrease the risk of developing breast cancer in the CIMBA studies also
decrease the risk of breast cancer in BRCA1 mutation carriers (HR 0.64, CI 0.5-0.099,
P=0.046) (Figure 12).

The variants in ANLN_rs3735400 (HR 0.56, CI 0.34-0.93,

P=0.025) (Figure 13), SIPA1L2_rs1547742 (HR 0.464, CI 0.28-0.77, P=0.003) (Figure
14), and MTHFSD_rs3751800 (HR 0.28, CI 0.14-0.58, P=0.0006) (Figure 15) all
decreased the risk of developing breast cancer in BRCA1 mutation carriers.
2.3.2 Functional study
As previously stated, candidate variants must be predicted damaging by variant
prediction software as well as affect a gene known or predicted to be a tumor suppressor
or oncogene.

The goal of these functional studies is to show evidence that these

predictions were accurate. To show evidence that the affected genes are oncogenes or
tumor suppressors, we made knockdown cell lines and measured the cellular growth
rate. It is hypothesized that if the affected gene is an oncogene, the knockdown cell line
will have a decreased growth rate in comparison to the control cell line. Furthermore, it
is also hypothesized that if the affected gene is a tumor suppressor, the knockdown cell
line will have an increased growth rate in comparison to the control cell line.
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Figure 11. SYNE1_rs2295190 cumulative risk of breast cancer
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Figure 12. ANKLE1_rs8100241 cumulative risk of breast cancer
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To show evidence that the predicted damaging variant is altering the function of the

affected gene, the function of the native allele and candidate modifier variant will be
measured in vitro. Because more specific experiments can be designed if a damaging
variant is affecting a known functional domain, only candidate modifiers in known
functional domains were analyzed. It is hypothesized that if the predicted damaged
variant is in a functional domain, this affected domain will be altered functionally.
While there is statistical evidence to show these five variants change the risk of
developing breast cancer in BRCA1 mutation carriers, it is unclear whether these
variants affect pre- or post-transformed breast cells.

Because post-transformed cell

lines with known BRCA1 mutations are more established than pre-transformed breast
epithelial cell lines, these affected genes would be analyzed in post-transformed breast
cancer cell lines. Both HCC1937 and MCF7 have mutations in BRCA1. HCC1937 has
a homozygote BRCA1 mutation genotype and is a basal-like ER/PR- normal Her2/neu
subtype. MCF7 has a heterozygote null BRCA1 genotype and is an ER/PR+ normal
Her2/neu luminal subtype.
Three criteria were set for the selection of candidate modifiers for functional studies.
1. The variants must be found to modify the risk of breast cancer in the cohort study
with statistical significant P<0.05.
2. The affected gene must be expressed in either MCF7 or HCC1937 cells.
3. The variant must be in a functional domain.
Variants found to modify the risk of breast cancer in the cohort study with statistical
significant (P<0.05) are ANLN_rs3735400, SIPA1L2_rs1547742, MTHFSD_rs3751800,
SYNE1_rs2295190 and ANKLE1_rs8100241.

To investigate the gene expression in

these two cell lines, RNA-seq data from both HCC1937 and MCF7 was downloaded
from the cancer genomics hub. The only candidate gene not expressed in either cell line
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was ANKLE1. Similarly, it has been previously shown that ANKLE1 is not expressed in
breast cell lines

67

.

Finally, two candidate modifiers, ANLN_rs3735400 and

SYNE1_rs2295190 were in known functional domains (Figure 16). ANLN_rs3735400 is
in a Nucleus Localization Sequence (NLS) and an mDia2-binding domain while
SYNE1_rs2295190 is in a KASH domain important for nuclear membrane localization
54,68

.

2.3.2.1 ANLN
2.3.2.1.1 Anillin and its role during cytokinesis
Actin-binding protein Anillin (ANLN) was first identified in Drosophila and plays important
roles in cytokinesis 69 . Anillin is localized to the nucleus during interphase and relocates
to the cortex after the nuclear envelope degrade. It then localizes to the equatorial
cortex in anaphase and at the cleavage furrow during telophase 70 . The ingression of
the cleavage furrow separates daughter cells at the end of mitosis (Figure 17). This
furrow ingression is driven by the assembly and contraction of actomyosin filaments,
forming a contractile ring.

Cytoskeletal protein Anillin has a pivotal role in the

organization of the network of cytoskeletal proteins at the cleavage furrow. This network
of cytoskeletal proteins acts as a scaffold connecting actomyosin filaments to the plasma
membrane 70-73 .
2.3.2.1.2 Anillin functional domains
Human Anillin is comprised of four functional domains: Myosin-2-binding domain, Actinbinding domain, RhoA-binding domain and the pleckstrin-homology (PH) domain. Anillin
also includes three other secondary structures: destruction box (Dbox), nuclear
socialization signal (NLS), and Src-homology-3-binding consensus sequences (SH3).
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Candidate modifiers of breast cancer risk chosen for functional

studies. Three criteria were set for the selection of candidate modifiers for functional
studies. Only SYNE1_rs2295190 and ANLN_rs3735400 were chosen.

Anillin-related proteins in cytokinesis
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Figure 17. Localization of Anillin during the cell cycle in mammals. Anillin protein
is depicted in red, chromosomes in black and microtubules, centrosomes, and spindleNucleus + cortex
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Fig. 3. Localization of Anillin-related proteins during the cell cycle in fission yeast, Drosophila and vertebrates. The distribution of Anillin-related proteins is
depicted in red, nuclei in grey, chromosomes in black, and microtubules, centrosomes and spindle-pole bodies in blue. ANI-1 also accumulates at the cleavage
furrows in C. elegans embryos, but its distribution in cycling cells has not been described.

kinase homologue Plo1p (Ohkura et al., 1995), which acts as a
positive cue because it promotes Mid1p nuclear export at mitotic
entry, increasing its concentration at the equatorial cortex (Bahler
et al., 1998). plo1 and mid1 interact genetically and physically
(Table 1) and Mid1p is phosphorylated during mitosis, but it is
unclear whether Plo1p directly phosphorylates Mid1p (Bahler
et al., 1998; Sohrmann et al., 1996). Computer simulations indicate
that nuclear export per se cannot explain the localization of Mid1p
to the medial region; instead, inhibitory mechanisms must also
prevent it spreading towards the cell ends (Padte et al., 2006). This
second inhibitory pathway involves Pom1p, a DYRK-family kinase
that controls polarized cell growth in fission yeast (Bahler and
Pringle, 1998). In pom1 mutants, Mid1p cortical distribution
spreads from the medial region to the non-growing end;
consequently, the division site also shifts towards the same nongrowing tip (Celton-Morizur et al., 2006; Padte et al., 2006). Thus,
Pom1p excludes Mid1p from the non-growing end and cooperates
with the Plo1p-dependent export of Mid1p from the nucleus to
localize Mid1p in a medial cortical band. Another, as-yetunidentified signalling pathway must also prevent Mid1p from
associating with the growing end.
Function of Anillin-related proteins
Drosophila
The function of Anillin in Drosophila has been elucidated by the
study of anillin (also known as scraps) mutants and by RNAidependent Anillin depletion in both cultured cells and flies. The
actomyosin ring is assembled normally in early telophase cells after
anillin RNAi, but it becomes severely disorganized in late telophase,
exhibiting aberrant F-actin accumulation and the formation of
numerous membrane blebs; this ultimately leads to a late failure of
cytokinesis (Echard et al., 2004; Somma et al., 2002). Thus, Anillin
is not required for F-actin accumulation at the furrow but rather for
proper organization of the contractile ring. Similarly, recruitment

O’Farrell, 2008). However, this unstable-furrow phenotype was not
observed in previous studies that used fixed preparations (Somma
et al., 2002; Straight et al., 2005) or in time-lapse analysis using a
similar cell line expressing a tubulin-GFP-encoding transgene
(Echard et al., 2004); the reasons for this discrepancy are unclear.
Analysis of anillin mutant animals demonstrated that Anillin is
essential for viability and functions in cytokinesis, for pole-cell
formation and for cellularization in Drosophila embryos. Indeed,
Anillin concentrates at the leading edge of the membrane
invaginations that are responsible for cellularization during early
embryogenesis, which are enriched in both F-actin and myosin II.
Furthermore, the localization of myosin II and septins is disrupted
in anillin mutant embryos (Field et al., 2005; Thomas and
Wieschaus, 2004). Anillin is also essential for the recruitment of
the septins Peanut and Septin 2 to the furrow in cultured Drosophila
cells. These proteins often mislocalize on central-spindle
microtubules following anillin RNAi, which suggests that septins
travel along spindle microtubules to reach the cortex where they
interact with Anillin (D’Avino et al., 2008). By contrast, septins
are not required for proper Anillin localization at the cleavage furrow
in cultured cells or embryos (Adam et al., 2000; D’Avino et al.,
2008). Finally, although Anillin is not required for RacGAP50C
localization to the spindle midzone (D’Avino et al., 2008; Gregory
et al., 2008), it does seem to be necessary for RacGAP50C
accumulation at the cortex in larval brain cells (Gregory et al., 2008).
Altogether, these data indicate that Anillin is essential for the proper
organization of actomyosin contractile structures, but not their initial
assembly or contractile activity, during both cytokinesis and
embryonic cellularization.
C. elegans
Of the three Anillin-related proteins in C. elegans (ANI-1, ANI-2
and ANI-3), only ANI-1 appears to be important for contractile-ring
formation (Maddox et al., 2005). RNAi of ani-3 does not lead to any
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The destruction box (Dbox) domain of Anillin binds to cadherin 1, type 1 (CDH1) and
anaphase prompting complex (APC), which is an ubiquitin protein ligase that
ubiquitinates Anillin, promoting its degradation during late mitosis/G1 74 . The nuclear
socialization signal (NLS) of Anillin binds the protein Important b2, which shuttles Anillin
from the cytoplasm to the nucleus during interphase 54 . The Src-homology-3-binding
consensus sequence (SH3) regulates the active state of adaptor proteins and increase
the substrate specificity of some tyrosine kinases. The Myosin-2 binding domain of
Anillin binds myosin-2, which is responsible for actin-based motility 73 . The Actin-binding
domain of Anillin binds actin, which is a protein that forms microfilaments 75 . The RhoA
domain of Anillin binds the gene Ras Homolog Family Member A (RhoA), which is a
member of the Rho family of small GTPases 72 . The pleckstrin-homolgy (PH) domain of
Anillin has been shown to bind septins at the plasma membrane 76 (Figure 18).
2.3.2.1.3 Anillin role in Cancer
Anillin has been found to be overexpressed in many different tumors. Furthermore,
Anillin expression has also been found to be a prognostic biomarker for cancer 61 . Other
studies have found that high nuclear fraction of ANLN was associated with large tumor
size, high histological grade, high proliferation and estrogen receptor (ER) negativity 77 .
Recently it has been shown that stable Anillin knockdown breast cancer cell lines MDAMB-231 and ZR-75-30 have decreased growth rates. These knockdown cells also have
increased percentage of cells in G2/M phase

62

.

This growth rate defect in breast

cancer cell lines give evidence that Anillin is not only a cancer biomarker but also an
oncogene in breast cancer.
2.3.2.1.4 ANLN knockdown
While both MDA-MB-231 and ZR-75-30 have decreased growth rates after ANLN
expression is decreased, these cell lines have normal BRCA1 expression.
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Figure 18. Secondary structures of Anillin protein in humans. Variant rs3735400 is
located in the N-terminal region of Anillin and causes a change from serine to tryptophan
in both the mDia2 binding motif and NLS domain.
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To test if breast cancer cell lines with BRCA1 mutations are affected by decreased
expression of ANLN, shRNA specific for ANLN was infected into both MCF7 and
HCC1937 cell lines.

As stated previously, HCC1937 has a homozygote BRCA1

mutation genotype and is a basal-like ER/PR- normal Her2/neu subtype cell line while
MCF7 has a heterozygote null BRCA1 genotype and is a luminal subtype cell line.
HCC1937 cells infected with shRNA_ANLN are not viable. All infected HCC1937 cells
die within two days.

This infection was repeated three times with similar results.

However, a stable ANLN knockdown in MCF7 showed a decreased growth rate in
comparison to the scrambled_shRNA infected MCF7 cells (Figure 19). This growth rate
defect is similar to the effects of shRNA_ANLN in both MDA-MB-231 and ZR-75-30
cells. These results show that BRCA1 mutated cell lines are equally sensitive, if not
more sensitive, to the decreased expression of ANLN. Furthermore, this gives evidence
that Anillin is a true oncogene.
2.3.2.1.5 Variant rs3735400 affects the function of Anillin
2.3.2.1.5.1 Nuclear localization
The variant rs3735400 is a nonsynonymous mutation that causes a serine to tryptophan
mutation of amino acid 65 in Anillin. This variant is localized upstream of the NLS of
Anillin (Figure 20). To investigate if the variant rs375400 alters the ability of Anillin to
localize to the nucleus, we transfected a N-terminal GFP-tagged Anillin construct into
HeLa cells (Figure 21). We found that Anillin with the variant rs3735400 had defected
nuclear localization in comparison to the wild type Anillin (Figure 22). While the function
of Anillin in the nucleus is unknown, it has been shown that Anillin with a mutated NLS
maintain the ability to rescue the bi-nucleated phenotype caused by an Anillin
knockdown 54 .
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Figure 19. Growth rate measurement of MCF7 infected shRNA_ANLN cells.
Knockdown of Anillin in MCF7 cells causes the growth rate to decrease in comparison to
the shRNA_Scrambled infected MCF7 cells. *P<0.05.
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Impor0n$β2$binding$mo0f$

Figure 20. N-terminus of Anillin has conserved NLS across different vertebrate
species.

The variant ANLN_rs3735400 affects the amino acid three amino acids

upstream from the NLS domain.

FIGURE 2. N terminus of anillin has distinct conserved regions across different vertebrate species and binds to importin !2 in a Ran-dependent
manner. A, alignment of the first 100 amino acids of anillin in different vertebrate species. B, consensus motifs for different classes of nuclear localization
sequences. C, comparison of the anillin bPY motif to other bPY motifs. D, recombinant His6-tagged importin " and !1 or !2 were incubated with a MBPanillin(1–151) fusion protein. The MBP-anillin fusion protein was re-isolated on amylose beads, and co-purifying His6-tagged proteins were detected by
SDS-PAGE and Western blotting. E, His6 importin !2-MBP-anillin binding reaction described in A was repeated in the presence and absence of recombinant
GST-RanGTP. Alignment of the anillin importin !2-binding motif with other known importin !2-binding motifs.

upon the expression of either GFP-anillin or the non-importin
!2-binding mutant, GFP-anillin(K68A/K69A/R70A) (Fig. 6, B
and C), indicating that importin !2 binding does not regulate
anillin’s cytokinetic function.
Cytosolic Accumulation of Anillin Disrupts Cell Shape—Successful cell division requires that cytokinesis takes place at the
end of mitosis, after the completion of chromosome segregation. Given anillin’s crucial role in linking the cell membrane
with the actin and septin cytoskeletons at the cytokinetic fur-

13504 JOURNAL OF BIOLOGICAL CHEMISTRY

row, we postulated that the presence of anillin in the cytoplasm
during interphase would disrupt the cellular cytoskeleton, thus
necessitating that anillin be kept inactive by sequestration in
the nucleus during interphase. To test this model, we transiently overexpressed GFP-anillin or GFP-anillin(K68A/K69A/
R70A) in HeLa cells. When overexpressed, GFP-anillin still
localized to the nucleus, and the cytosolic actin organization
and cell shape were similar to cells not expressing GFP-anillin
(Fig. 7A). In contrast, in 93 ! 3.5% of cells overexpressing GFPVOLUME 290 • NUMBER 21 • MAY 22, 2015
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Figure 21. Anillin constructs transfected into HeLa cells. To analyze the effects of
ANLN_rs3735400 on Anillin nuclear localization, a full length GFP tagged Anillin_wt and
Anillin_(S65W) were transfected into HeLa cells. Both proteins are able to localize to the

lear localization sequence of anillin lies in the first 91 amino acids. A, schematic of the domain organization of anillin and the GFP-anillin
s expressed in HeLa cells shown in B. FL, full-length anillin sequence; wt, wild type sequence. B, micrographs of HeLa cells transiently expressing
nucleus.
anillin fusion proteins described
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Figure 22. ANLN_rs3735400 affects the nuclear localization of Anillin. Different
GFP-Anillin fusion proteins in HeLa cells showing a ratio change of GFP fluorescence
between the nuclear and cytoplasmic compartments. **P<0.005.
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2.3.2.1.5.2 Knockdown growth rate rescue
Next, we investigated whether ANLN with the variant rs3735400 can rescue the growth
rate phenotype caused by an Anillin knockdown in MCF7 cells. It has been shown that
the first 115 amino acids of Anillin is required for the proper localization of mDia2 to the
cleavage furrow

78

. Furthermore, truncated Anillin without the first 115 amino acids

abolishes the ability of Anillin to rescue the bi-nucleated phenotype caused by an Anillin
knockdown 78 . Because rs3735400 affects an amino acid within the first 115 amino
acids (ANLN_S65W), it was hypothesized that this variant will disrupt the ability of Anillin
to rescue the growth rate defect caused by an infection of shRNA_Anillin in MCF7 cells.
Growth rate of iInfected shRNA_ANLN cells rescued with transfected ANLN_wt was
similar to cells with endogenous levels of Anillin protein.

However, infected

shRNA_ANLN cells transfected with ANLN_(S65W) showed similar growth rates to cells
that were infected with shRNA_ANLN and transfected with an empty vector (Figure 23).
This result suggests that the variant rs3735400 may alter the function of ANLN and its
ability to regulate cellular proliferation.
2.3.2.2 SYNE1
2.3.2.2.1 SYNE1 and its role in nuclear membrane stability
Nesprin-1 (SYNE1) belongs to a family of spectrin-repeat proteins. Alternate initiation
and splicing of SYNE1 generate multiple isoforms that vary greatly in size and function.
Giant isoform Nesprin-1 is composed of a spectrin-repeat rod domain linked to a
C-terminal transmembrane KASH (Klarsicht-ANC-SYNE-homology) domain, which
mediates nuclear membrane localization, and N-terminal alpha-actinin-type actin-binding
domain (ABD) 79 . Nesprin-1 is an essential component of the nuclear envelope and is
part of the LINC (linker of nucleoskeleton and cytoskeletion) complex.
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Figure 23.

ANLN_rs3735400 inhibits Anillin ability to rescue the ANLN

knockdown. The ANLN knockdown could be rescued with ANLN_wt. ANLN_(S65W)
protein was unable to rescue the knockdown growth rate defect and had a similar rate to
the knockdown ANLN transfected with an empty vector. *P<0.05, **P<0.005.
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Disruption of the nuclear-cytoskeleton connections affects the stability, size, and shape
of the nucleus and alters cell migration and mechanical properties of the cell

80-83

.

2.3.2.2.2 SYNE1 and cancer
Downregulation of Drop1, an N-terminal isoform of Nesprin-1 has been observed in early
tumor stages in a wide range of human carcinomas 84 . Furthermore, data from TCGA
and other publications have shown that SYNE1 is frequently mutated in both breast and
colorectal cancer 85 . It has also been reported that Nesprin-1 has a role in DNA damage
response and DNA repair and mismatch repair pathways, which are determinants of
genetic instability in cancer.

It was observed that human foreskin cells (HFF1)

transfected with siRNA_SYNE1 had a larger percentage of gamma-H2AX positive cells
than cells with endogenous levels of SYNE1. Gamma-H2AX is a biomarker for DNA
double-strand breaks 86 . These siRNA_SYNE1 HFF1 cells also have defects in size
and shape of the nucleus. It is hypothesized that this genomic instability is occurring in
these knockdown cells due to a combination of alterations in the DNA damage response
and mismatch repair pathways and increased physical stress of the nuclear membrane.
This increase in DNA double-strand breaks is especially interesting to this study
because a critical function of BRCA1 is to repair DNA double-strand breaks 87 .
The variant SYNE1_rs2295190 has previously been associated with an increased risk of
developing invasive epithelial ovarian cancer 60 . The result of the cohort study also
associated rs2295190 with an increased risk of developing breast cancer in BRCA1
mutation carriers. The mutation frequency in cancer, function in genomic stability, and
association of the predicted damaging variant rs2295190 with an increase in breast and
ovarian cancer risk gives evidence that SYNE1 is a tumor suppressor.
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2.3.2.2.3 Knockdown SYNE1
To investigate the role of SYNE1 in breast cancer, a stable shRNA_SYNE1 MCF7 cell
line was made. HCC1937 cells were not infected with SYNE1_shRNA because SYNE1
is not expressed in this cell line. SYNE1 knockdown MCF7 cells have an increased
growth rate in comparison to the Scrambled_shRNA infected MCF7 cells (Figure 24).
This increased growth rate in MCF7 cells and the increased genomic instability in HFF1
cells gives further functional evidence that SYNE1 is a tumor suppressor.
2.3.2.2.4 Variant rs2295190 affects the function of Nesprin-1
The variant rs2295190 is a nonsynonymous mutation that causes a leucine to
methionine alteration of amino acid 8693 in Nesprin-1 (Figure 25). This alteration is in
the neck region of the KASH domain, which is the nuclear transmembrane domain of
Nesprin-1 (Figure 26). Because this amino acid is very conserved in multiple organisms
and located near the nuclear transmembrane domain, we hypothesize that this variant is
altering the ability of Nesprin-1 to localize to the nuclear membrane 55 . To test this
hypothesis, a N-terminal truncated N-terminal tagged GFP Nesprin-1 construct was used
to investigate whether this variant can alter the ability of truncated Nesprin-1 to bind to
the nuclear membrane (Figure 27).

As previously published, this construct with the

native allele binds tightly around the nuclear membrane.

However, once the native

amino acid was changed from a leucine to a methionine, the GFP-Nesprin-1_(L8693M)
was dispersed throughout the cytoplasm and seemed to lose the ability to localize tightly
to the nuclear membrane. This localization alteration gives evidence that the variant
rs2295190 can alter the function of the tumor suppressor Nesprin-1.
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Figure 24. Growth rate measurement of MCF7 infected shRNA_SYNE1 cells.
Knockdown of Nesprin-1 in MCF7 cells causes the growth rate to increase in
comparison to the shRNA_Scrambled infected MCF7 cells. *P<0.05.
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L-M
rs2295190

Figure 25. Secondary structures of Nesprin-1 protein in humans. Nesprin-1 binds
to the F-Actin and the nuclear membrane.

Variant rs2295190 is located in the C-

terminal nuclear transmembrane KASH domain of Nesprin-1 and causes a leucine to
methionine amino acid change.
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2.4 Discussion
2.4.1 Statistical association that common variants can modify the risk of breast
cancer in BRCA1 mutation carriers
Prior to this study, the only evidence that common variants could affect the risk of
developing breast cancer in BRCA1 mutation carriers was from GWAS studies. GWAS
studies are purely based on statistical analysis and the variants identified are not
selected based on biological plausibility.

There has been no published studies to

functionally link the variants found in these GWAS studies to breast cancer.

The

ultimate goal of this study was to identify variants that statistically change the risk of
developing breast cancer in BRCA1 mutation carriers as well as provide functional
evidence linking these variants to breast cancer development.
To identify breast cancer risk variants, we sequenced 27 high risk and 27 low risk
BRCA1 mutation carriers with exome next-generation sequencing.

We then applied

multiple biological and statistical filters to identify variants that are linked both statically
and functionally to breast cancer risk.
The statistical association results identified five variants (ANKLE1_rs8100241,
ANLN_rs3735400, SIPA1L2_rs1547742, MTHFSD_rs3751800 and SYNE1_rs2295190)
that both modify the risk of breast cancer with statistical significant and are predicted to
alter genes previously linked to cancer development. A major concern for this study was
that the case control sample size would be too small to accurately identify risk modifying
variants. Five of the variants identified in the case control study maintained statistical
significance when re-examined in the more statistically powerful cohort study. These
results provide evidence that the case control study is powerful enough to identify risk
modifying variants. Furthermore, the variant ANKLE1_rs8100241 identified in the case
control study was previously identified in other larger GWAS studies to modify the risk of
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breast cancer in BRCA1 mutation carriers 42 . The other four variants found in this study
are newly identified BRCA1 mutation carrier genetic risk modifiers.

While all of the

variants can be linked to cancer development, two of the five variants were chosen for
further investigation with functional studies.
2.4.2 Functional studies with ANLN_rs3735400 and SYNE1_rs2295190
There were two aims for these functional studies. The first aim was to provide evidence
that the affected gene could alter the growth rate of BRCA1 mutated breast cancer cells.
The second aim was to provide evidence that the identified risk-modifying variants could
alter the function of the affected gene. Only two of the five variants, ANLN_rs3735400
and SYNE1_rs2295190, were included in the functional studies because they were the
only variants that affected a gene expressed in BRCA1 mutated breast cancer cells and
are located in a known functional domain.
2.4.2.1 ANLN_rs3735400
It was shown that the predicted damaging variant ANLN_rs3735400 decreases the risk
of breast cancer in BRCA1 mutation carriers.

Because damaging variants most

commonly cause a loss of function genetic phenotype, it would be predicted that ANLN
is an oncogene. This is not the first time ANLN was predicted to be an oncogene. ANLN
has previously been shown to be overexpressed in different types of cancer and is a
biomarker for poor prognosis in breast cancer 61 . Furthermore, this functional study has
shown that ANLN expression is linked positively to the proliferation rate of BRCA1
mutation breast cancer cell lines, providing further evidence that ANLN is an oncogene.
Next, we investigated whether ANLN_rs3735400 could alter the function of Anillin. First,
we showed that ANLN_rs3735400 could decrease the ability of Anillin to localize to the
nucleus. While the function of ANLN in the nucleus is currently unknown, it has been
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hypothesized that Anillin is sequestered into the nucleus during interphase to control the
Anillin ability to reorganize the actin filaments in a cell cycle dependent manner.
Furthermore, the ability of ANLN to localize to the nucleus has been shown to be
independent of its function during cytokinesis.
The ability of ANLN_rs3735400 to rescue the growth rate caused by the shRNA_ANLN
knockdown was investigated next. It was shown that while ANLN_wt could fully rescue
the phenotype caused by shRNA_ANLN, ANLN_(S65W) was unable to change the
growth rate defect caused by shRNA_ANLN in MCF7 cells. This was not suppressing
as it has been shown that the N-terminal 115 amino acids of ANLN is critical to maintain
Anillin ability to function during cytokinesis. The N-terminal 115 amino acids were found
to be critical for the localization and activation of the formin mDia2 to the cleavage
furrow. It has been shown that cells with altered mDia2 do not form F-actin required for
transition through cytokinesis. Because the variant ANLN_rs373540 is within this Nterminal region, we hypothesize that this variant ANLN_(S65W) is inhibiting ANLN ability
to interact with mDia2.
2.4.2.2 SYNE1_rs2295190
It was shown that the predicted damaging variant SYNE1_rs2295190 increases the risk
of breast cancer in BRCA1 mutation carriers.

Because damaging variants most

commonly cause a loss of function genetic phenotype, it would be predicted that SYNE1
is a tumor suppressor. This is not the first time SYNE1 has been predicted to be a tumor
suppressor. It has previously been shown that SYNE1_rs2295190 is associated with an
increase in risk of ovarian cancer

60

.

In addition, SYNE1 has been shown to be

frequently mutated in different types of cancer and loss of SYNE1 is known to increase
genomic instability 68,84 . Furthermore, this functional study has shown that decreasing
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the expression of SYNE1 increases the proliferation rate of a BRCA1 mutation breast
cancer cell line, providing more evidence that SYNE1 is a tumor suppressor.
Next, it was investigated whether SYNE1_rs2295190 could alter the function of
Nesprin-1. Giant Nesprin-1 has been shown to link the cytoskeleton to the
nucleoskeleton by binding F-actin in both the cytosol and the nuclear membrane. The
variant SYNE1_rs2295190 changes a highly conserved amino acid leucine to a
methionine in the neck region of the transmembrane KASH domain. This study showed
that the variant SYNE1_rs2295190 can alter the ability of Nesprin-1 to bind to the
nuclear membrane. It is hypothesized that this alteration of Nesprin-1 localization can
affect the nucleoskeleton linkage, which has been shown to affect the function of both
DNA repair and mismatch proteins.
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Phasing the genome with NGS
Information derived from genomic phasing can provide information on the genetic origin
of disease and how DNA nucleotide alterations interact in cis. However, current nextgeneration sequencing techniques generate a single consensus sequence without
distinguishing between variants on homologous chromosomes. Scientists and engineers
are actively advancing genome phasing capabilities by redesigning methods of genomic
library construction and improving the NGS platform technology so longer reads can be
sequenced.
The current experimental approaches used to phase the genome are too experimentally
laborious to be commonly used. The goal of my first project was to analyze a new
experimentally non-laborious method of NGS library preparation hypothesized to
increase the amount of phasing information derived from NGS data. This new method
involved cutting the genomic DNA with restriction enzymes instead of random shearing.
It was shown that NGS libraries processed with restriction enzymes provide more
phasing information than libraries made with random shearing. However, there were
some technical issues with the reads generated from restriction enzyme libraries. First,
libraries generated with a single restriction enzyme is only able to cover 40-50% of the
exome. With similar read depths, a NGS library made with random shearing covered
about 75% of the exome. However, exome coverage was greatly increased when NGS
libraries were generated with a combination of four different restriction enzymes. While
this method increases the exome coverage, the cost, time and quantity of genomic DNA
required to process four libraries is more than that needed to make a single sonication
derived NGS library.
Another issue was that the reads from restriction enzyme libraries were difficult to map
to the reference genome. Furthermore, these difficulties might also be the reason why
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many variants called from these reads were false variants. These results are likely due
to reads that are too small to be aligned accurately to the reference human genome.
This technical issue and can be addressed by making changes to the methodology of
restriction enzymes NGS library preparation. Another option is to set more strict filters to
remove lower quality reads before mapping to the reference genome. However, it may
make more fiscal sense to remove these reads before sequencing to save on Illumina
sequencing running cost. For now, it seems that the current gain-of-phasing information
derived from restriction enzyme NGS libraries does not outweigh the technical issues
with this method.
Future directions for phasing the genome with NGS
It is proposed that the ideal option to increase the number of phased variants while
maintaining a low variant error rate is to modify the sonication method of shearing
genomic DNA. By pooling together two libraries, one library with the recommended
fragment size and one library with a larger fragment size, the ability to construct larger
contigs would increase and the sensitivity and specificity to call variants would be
maintained.
The NGS platform technology is currently the limiting factor in our ability to phase the
genome with high-throughput sequencing.

However, as NGS platform technology

improves, the ability to phase the genome will also increase (during my time as a PhD
student, Illumina sequence lengths increased from 100bp to 150bp). There are also
talks of a fourth generation sequencing platform (Oxford Nanopore) that has no DNA
fragment size limitations. If this system works as described, it may be the solution to
phasing the genome efficiently. This technology will open up new fields of research that
is currently underexplored.
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Genetic modifiers of breast cancer risk of BRCA1 mutation carriers
Risk of breast cancer is caused by a combination of environment and genetic modifiers.
BRCA1 mutation carriers from familial breast cancer families have a wide range of risk
(44-75%) of developing breast cancer by age 70 15 . There are many known factors that
can modify BRCA1 mutation carrier risk.
Currently, there are limited risk assessments and treatment options for the intervention
of breast cancer in BRCA1 mutation carriers, leading some carriers to undergo invasive
mastectomy.

By identifying germline modifiers, physicians can provide better

personalize cancer risk assessments to BRCA1 mutation carriers and researchers can
potentially design new preventative therapies to lower the risk of cancer in these
carriers.
The majority of known modifying factors in BRCA1 mutation carriers are environmental.
One reason for this is that the technology to perform GWAS studies has only been
available for eleven years. Furthermore, because information about genetic modifiers is
from GWAS studies, which can only associate variants with changes of cancer risk, the
variants that cause risk of breast cancer to change are currently unknown. To date,
there have been no studies to show that genetic variants can functionally changing the
risk of breast cancer in BRCA1 mutation carriers. The goal of this study was to identify
variants that modify the risk of developing breast cancer in BRCA1 mutation carriers and
provide functional evidence linking these variants to breast cancer development.
This study is the first to identify new risk modifying variants (ANLN_rs3735400,
SYNE1_rs2295190,
ANKLE1_rs8100241)

SIPA1L2_rs1547742,
based

on

statistical

MTHFSD_rs3751800,
and

biological

evidence.

and
While

ANKLE1_rs8100241 was previously identified by GWAS studies to statistically decrease
the risk of breast cancer in BRCA1 mutation carriers, there was no biological evidence
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that this variant was functional important 59 . SYNE1_rs2295190 was the only variant
found to increase the risk of breast cancer in BRCA1 mutation carriers. The variant
SYNE1_rs2295190 has previously been shown to statistically increase the risk of
ovarian cancer 60 . Similar to the variant in ANKLE1, SYNE1_rs2295190 was previously
identified without biological evidence that this variant was functional important.

The

three newly identified risk modifying variants ANLN_rs3735400, SIPA1L2_rs1547742,
and MTHFSD_rs3751800 were all shown to decrease the risk of breast cancer in
BRCA1 mutation carriers.
The variant MTHFSD_ rs3751800 was shown to have the greatest modifying effect of
breast cancer risk in BRCA1 mutation carriers. BRCA1 mutation carriers with the variant
MTHFSD_ rs3751800 had a 70% lower risk of developing breast cancer than BRCA1
mutation carriers without this variant. Furthermore, this variant was also found to be the
most statistically significant. While this study has shown evidence that a variant in the
gene MTHFSD is associated with lower breast cancer risk, there have been no studies
to analyze the function of MTHFSD. MTHFSD was previously identified in only one
study, during a screen for genes that bind to p53

64

.

While there is evidence that

MTHFSD and p53 bind, the consequence of MTHFSD binding to p53 remains unknown.
The second goal of this study was to provide functional evidence that common variants
can modify the risk of breast cancer in BRCA1 mutation carriers. We decided to focus
on the variants ANLN_rs3735400 and SYNE1_rs2295190 because they are both in
functional domains and ANLN and SYNE1 are both expressed in cell lines with BRCA1
mutations.
While there is published evidence that ANLN is an oncogene and SYNE1 is a tumor
suppressor, the function of these genes have not been investigated in a breast cancer
cell line with BRCA1 mutations. As expected, decreasing the expression levels of the
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oncogene ANLN caused a decrease in growth rate of BRCA1 mutated breast cancer
cells compared to cells with endogenous expression of ANLN. It was also shown that
decreasing the expression levels of the tumor suppressor SYNE1 increased the growth
rate of BRCA1 mutation breast cancer cells in comparison to cells expressing
endogenous levels of SYNE1.

These results provide functional evidence that both

ANLN and SYNE1 can alter the proliferation rate of human breast cancer cells.
Furthermore, there is now functional evidence that ANLN and SYNE1 can regulate the
growth rate of BRCA1 mutation breast cancer cells. These results provide evidence that
ANLN and SYNE1 are good candidate genes that may be able to modify the risk of
breast cancer in BRCA1 mutation carriers.
Next, and perhaps more importantly, we investigated whether these variants could alter
the function of the affected gene. We first showed that the variant ANLN_rs3735400
affected the proper nuclear localization of Anillin. While the function of Anillin in the
nucleus is unknown, previous studies have shown that the ability of Anillin to localize to
the nucleus does not affect the ability of Anillin to rescue the knockdown phenotype.
However, because the variant is also in the mDia2-binding domain of Anillin, which is
critical for the ability of Anillin to rescue the knockdown phenotype, we investigated
whether Anillin with ANLN_rs3735400 could rescue the knockdown phenotype. It was
shown that the full length Anillin with the ANLN_rs3735400 variant was unable to rescue
the decreased growth rate caused by the shRNA_ANLN in MCF7 cells. It has been
shown that the N-terminal 115 amino acids of ANLN is critical to maintain Anillin function
during cytokinesis 78 . Because the variant ANLN_rs3735400 affects the N-terminal 65
amino acid, we hypothesized that this variant ANLN_(S65W) is inhibiting ANLN ability to
interact with mDia2.
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These results provide evidence that the variant ANLN_rs3735400 can alter the ability of
Anillin to drive proliferation. While it remains unknown why Anillin with ANLN_rs3735400
is unable to restore the proliferation rate, we hypothesize that ANLN_rs3735400 is
affecting proper Anillin mDia2 binding during cytokinesis. All of the functional results
collected from this study provide evidence that BRCA1 mutation carriers with a misfunctioning oncogene, Anillin, have a decreased risk of breast cancer in comparison to
carriers with a fully functional Anillin oncogene.
Next, we tested the ability of variant SYNE1_rs2295190 to disrupt the localization of a
truncated Nesprin-1 to the nuclear membrane. The major function of giant Nesprin-1 is
to link the cytoskeleton to the nucleoskeleton by binding F-actin in the cytosol with the
nuclear membrane. An alteration of Nesprin-1 nuclear membrane localization can affect
the nucleoskeleton linkage, which has been shown to affect the function of both DNA
repair and mismatch proteins. This disruption of DNA repair and mismatch proteins can
increase genomic instability 68 . It was shown that the variant SYNE1_rs2295190 greatly
alters the ability of Nesprin-1 to bind to the nuclear membrane. All of the functional
results collected from this study give evidence that BRCA1 mutation carriers with a
mutated tumor suppressor, Nesprin-1, have an increased risk of breast cancer in
comparison to carriers with a fully functional tumor suppressor.
Future directions for genetic modifiers of breast cancer risk of BRCA1 mutation
carriers
While three of the five variants (SIPA1L2_rs1547742, MTHFSD_rs3751800, and
ANKLE1_rs8100241) were not functionally studied in this project, there is evidence that
these genes are important in cancer development.

Because the function of MTHFSD,

SIPA1L2 and ANKLE1 in vertebrates are unknown, we would propose to first analyze
these genes with a proteomic approach. Once the general function and binding partners
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of these genes are known, one can start designing experiments to test whether these
variants alter the function of the affected gene and if these genes are important for
cancer development.
The role of these five variants in the normal population should also be investigated.
While these alleles may be beneficial in lowering the risk of breast cancer in the BRCA1
population, they could have deleterious effects in the non-BRCA1 mutated population.
Conversely, these common variants may lower the risk of cancer in the normal
population. One would expect that variants that decrease the risk of cancer may be
selected for and should be found at a high frequency in the general population.
However, this is only true if the variant is not causing a more severe or higher risk state
than the benefit of the decreased cancer risk.
It would also be interesting to calculate the frequency of these variants in populations
with a high amount of BRCA1 mutation carriers. If these variants only decrease risk of
cancer in BRCA1 mutation carriers, one would expect that these variants would be more
frequent in populations with a higher frequency of BRCA1 mutation carriers.
Another important goal is to determine how different genetic modifiers affect each other
and within the context of known environmental modifiers. These types of studies can be
difficult to perform because population size for these studies must increase greatly with
the number of variables being accounted for. However, knowledge gained from these
studies would greatly improve the ability to accurately calculate risk assessment for
BRCA1 mutation carriers.
More studies should also be performed to investigate how the variant ANLN_rs3735400
is affecting the function of Anillin. Even though the variant ANLN_rs3735400 is located
in the mDia2 binding domain and a truncated Anillin lacking the mDia2 domain has a
similar inability to rescue a phenotype caused by an ANLN knockdown, it is unclear
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whether ANLN_rs3735400 affects the ability of Anillin to bind to mDia2. To investigate
this, we propose using a protein complex immunoprecipitation pull-down assay.
Furthermore, because ANLN_wt has been shown to co-localize with mDia2 at the cleave
furrow during cytokinesis, we can also use immunofluorescence to investigate the
localization of ANLN_(S65W) and mDia2 during cytokinesis. These experiments would
provide evidence on how ANLN_rs3735400 affects the function of Anillin.
Further studies should also be performed to investigate the function of Anillin and
Nesprin-1 in non-transformed breast epithelial cells.

We propose to use the non-

transformed breast epithelial cells MCF10a and MCF10a BRCA1-/- cells. By inducing
the variants with the Crisper/Cas9 system, we could change the specific nucleotide while
maintaining the endogenous expression of the gene. Results from these experiments
will help clarify whether ANLN and SYNE1 are important for tumorigenesis or if they are
only important in post-transformed breast cells.
Results from this study would provide insight into whether manipulation of these genes
or pathways could be used as cancer therapy and/or a cancer preventive therapy. For
example, if these studies provide new evidence that linkage between the cytoskeleton
and nucleoskeleton influences breast cancer risk in BRCA1 mutation carriers, one could
design preventative therapies to increase this linkage. This type of therapy may be used
to decrease the risk of breast cancer in BRCA1 mutation carriers. Furthermore, if this
linkage is important for genomic stability in all cell types, this therapy could be used to
lower the risk of cancer in non-carriers as well.
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Abstract Partner and localizer of BRCA2 (PALB2),
plays an important functional role in DNA damage repair.
Recent studies indicate that germline mutations in PALB2
predispose individuals to a high risk of developing familial
breast cancer. Therefore, comprehensive identification of
PALB2 germline mutations is potentially important for
understanding their roles in tumorigenesis and for testing
their potential utility as clinical targets. Most of the previous studies of PALB2 have focused on familial breast
cancer cases with normal/wild-type BRCA1 and BRCA2
(BRCAx). We hypothesize that PALB2 genetic mutations
also exist in individuals with BRCA mutations (BRCA?).
To test this hypothesis, PALB2 germline mutations were
screened in 107 exome data sets collected from familial
breast cancer families who were either BRCA1? or
BRCAx. Two novel heterozygous mutations predicted to
alter the function of PALB2 were identified (c.2014G[C,
p.E672Q and c.2993G[A, p.G998E). Notably, both of
these mutations co-existed in BRCA1? and BRCA1x
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families. These studies show that mutations in PALB2 can
occur independent of the status of BRCA1 mutations, and
they highlight the importance to include BRCA1? families
in PALB2 mutation screens.
Keywords BRCA1 ! PALB2 ! Familial breast cancer !
Predisposition
Abbreviations
PALB2 The partner and localizer of BRCA2
BRCA1 Breast cancer 1, early onset
BRCA2 Breast cancer 2, early onset
MAF
Minor allele frequency
LOVD
Leiden open variation database

Introduction
Partner and localizer of BRCA2 (PALB2), plays important
roles in double-stranded DNA damage repair through interaction with BRCA1, BRCA2, and RAD51 [1, 2]. Studies
by Xia et al. (2007) determined that homozygous mutations
in PALB2 cause Fanconi’s anemia [3]. Subsequent studies
by Chen et al. (2008) and Janatova et al. (2013) found that
women with a clear family history of breast cancer and
carried heterozygous mutations in PALB2 had an increased
risk of developing familial breast cancer [4, 5]. Further, a
large-scale study by Antoniou et al. (2014), which involved
362 members of 154 BRCAx breast cancer families with
PALB2 mutations, indicated that the risk carriers of
heterozygous PALB2 mutations have for developing breast
cancer by age 70 are as high as 35 % [6]. This risk is much
greater than previously thought and is similar to that caused
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by BRCA2 mutations, which are well known to predispose
women to breast and ovarian cancer [7]. Moreover, the
higher rate of PALB2 mutations implies the high risk of
developing breast cancer in the carriers. Thus, PALB2
mutations can potentially serve as genetic markers for the
clinical diagnosis, treatment, and prognosis of breast cancer. However, before this can occur, it is necessary to determine the full spectrum of PALB2 mutations in familial
breast cancer. This can be accomplished by screening a
large number of families with a history of breast cancer for
PALB2 mutations [8], similar to the extensive searches for
BRCA1 and BRCA2 mutations (https://research.nhgri.nih.
gov/projects/bic/).
It remains undetermined if PALB2 mutations are
specifically present in familial breast cancer with normal/
wild-type BRCA1 and BRCA2 (BRCAx) or if PALB2 mutations universally predispose individuals to familial breast
cancer regardless the mutation status of BRCA1 and
BRCA2. This knowledge is expected to help determine if
PALB2 germline mutations can be used as specific markers
to BRCAx familial breast cancer or if PALB2 germline
mutations can be used as general markers for familial
breast cancer. Most efforts made toward locating PALB2
mutations have screened cases of BRCAx familial breast
cancer [7, 8]. Our study extends to include breast cancer
family members who inherited damage mutations in
BRCA1 (BRCA1?). We analyzed PALB2 germline mutations in 107 cases of both BRCA1? and BRCAx familial
breast cancer and identified two heterozygous mutations
predicted to damage the function of PALB2 (c.2014G[C,
p.E672Q and c.2993G[A, p.G998E). Most importantly,
both mutations were shared between BRCA1? and BRCAx
familial breast cancer families.

Materials and methods
Informed consent was obtained from all study participants.
Institutional Review Boards (IRBs) at both the University
of Nebraska Medical Center and Creighton University
School of Medicine approved the study.
Exome sequencing and DNA mapping processes applied
have been described in previous studies [9–11]. Briefly,
samples that were screened for PALB2 mutations included
both BRCA1? and BRCAx carriers (Table 1). Exome libraries were constructed using TruSeq Exome Enrichment
Kit (Illumina, Inc., San Diego, CA). A HiSeqTM 2000 sequencer (Illumina) was used to collect exome sequences
with paired-end reads (2 9 100). Sequences were then
mapped to the human genome reference sequence hg19
using a sequence alignment tool, Bowtie2 [12]. Next,
VarScan 2 software was used to call the variants from the
mapped sequences [13]. These variants were then
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Table 1 Exome-sequenced cases
Number of families

Number of cases

Number of families
BRCA1?

26

56

BRCAx

32

51

Female

–

104

Male

–

3

Breast cancer

–

77

No breast cancer

–

30

Gender

Cancer status

annotated using ANNOVAR [14], the PALB2 reference
sequence NM_024675 [RefSeq; National Center for
Biotechnology Information (NCBI)], Single Nucleotide
Polymorphism Database 137 (dbSNP137), the 1000 Genomes Project [15], and the Exome Variant Server 6500
(http://evs.gs.washington.edu/EVS/). From the called variants, those originating in the PALB2 coding region were
selected for further analysis. Variants that caused synonymous changes in PALB2 were removed. From the remaining variants, those that caused damaging
consequences were further predicted using both sorting
intolerant from tolerant (SIFT) [16] and PolyPhen-2 [17]
programs, and then validated using Sanger sequencing.

Results
To identify the damage mutations in PALB2, exome data
were mined from 107 cases from 58 different families
with familial breast cancer (Table 1). Of these 107 cases,
56 were from 26 families with BRCA1? and 51 were
from 32 families with BRCAx; 104 cases were women,
and three cases were men; 77 cases were diagnosed with
breast cancer, and 30 cases were unaffected family
members.
Ninety variants across the entire PALB2 genomic region
were identified from the exome data. Six variants were in
coding exons, of which two were synonymous, and four
were nonsynonymous. Using Sanger sequencing, the two
nonsynonymous mutations were confirmed as c.2014G[C,
p.E672Q, and c.2993G[A, p.G998E (Table 2, Fig. 1a).
Further, both SIFT and PolyPhen-2 programs predicted
each mutation to damage the function of PALB2. Each
mutation is listed in dbSNP137 at minor allele frequency
(MAF) of 0.024 and 0.018, respectively. Notably, neither
mutation was reported in the PALB2 study by Antoniou
et al. [6], but both mutations were listed in the PALB2
LOVD database (LOVD v.2.0 Build 36). The mutation
c.2014G[C, p.E672Q, was located at the MRG15
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Table 2 Two mutations identified in PALB2
Base change

c.2014G[C

c.2993G[A

Amino acid
change

Position (hg19)

p.E672Q

chr16:23641461

p.G998E

chr16:23634293

BRCA
status

Family

?

1

?

2

?

3

-

4

-

5

-

6

?
?

2
3

-

4

-

5

-

6

dbSNP138

MAF

LOVD

SIFT

PolyPhen-2

Score

Prediction

Score

Prediction

rs45532440

0.024

10,092

1

Damage

0.952

Damage

rs45551636

0.018

10,135

1

Damage

0.996

Damage

families. The data also indicate that multiple mutations in
PALB2 can exist in the same family. Figure 2 shows the
pedigree of each BRCA1? family. Each family contains
the following different mutations in BRCA1: ins6kbEx13ter1460 (family 1), 332-11T-Gins59-ter75 (family 2), and
300Cys-Gly (T-G) (family 3). The distribution in BRCAx
families cannot be determined because only the proband
DNA samples in each family were available for the study.
However, further studies that extend to BRCAx families are
expected to help better quantify this distribution.

Discussion

Fig. 1 Mutations in PALB2. a Sanger sequencing validation showing
the two mutations was heterozygous mutations in PALB2. b Location
of the two mutations of c 2014G[C p.E672Q and c.2993G[A
p.G998E in PALB2

interaction domain, and the mutation of c.2993G[A,
p.G998E, was located at the BRCA2, RAD51, and POLH
interaction domain (Fig. 1b).
The mutation of c.2014G[C, p.E672Q, was detected in
three families with BRCA1? (families 1, 2, and 3), and the
same mutation was also detected in three families with
BRCAx (families 4, 5, 6). Similarly, the mutation
c.2993G[A, p.G998E, was detected in two families with
BRCA1? (families 2 & 3) and three families with BRCAx
(families 4, 5, 6). Interestingly, the mutation of
c.2014G[C, p.E672Q, detected in BRCA1? family 2 was
present in an unaffected family member, suggesting that
this mutation had low penetrance in this individual. The
two mutations were distributed in eight cases from three
BRCA1? families and six cases from three BRCAx

Germline mutations in PALB2 have been considered
specific to BRCAx familial breast cancer [5, 6, 18]. However, and importantly, our analysis shows that the same
germline mutations can be present in both BRCA1? and
BRCAx families. This finding suggests that PALB2 mutations can occur independently of the BRCA status. Further,
it suggests that, in addition to BRCAx breast cancer
families, BRCA1? breast cancer families should be included in PALB2 screening. Notably, each mutation identified in this study is listed in the dbSNP, which could
suggest that they are normal polymorphisms. However, the
two mutations are rare in the normal population, as judged
by their low MAF value (0.024 for c.2014G[C, p.E672Q,
and 0.018 for c.2993G[A, p.G998E). Moreover, rare
variants are known to enrich genetic predispositions for
familial diseases [19], as demonstrated by rare variants in
XRCC2, FANCC, and BLM that have been found to be
genetic predispositions for familial breast cancer [20–24].
Further, six of the 50 PALB2 damage mutations identified
in the study by Antoniou et al. (2014) were also rare
variants [6]. Our study suggests that an even greater
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Fig. 2 Pedigree of the three BRCA1 ? familial breast cancer
families with the two mutations in PALB2. BRCA1 mutations in the
three families are family 1 (ins6kbEx13-ter1460), family 2 (332-11T-
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Gins59-ter75), and family 3 [300Cys-Gly (T-G)]. Exome data from
eight members in family 1, two members in family 2, and two
members in family 3 were used in the study
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number of PALB2 mutations can exist in familial breast
cancer, particularly in families with BRCA1?. Additional
screens in more BRCA1? breast cancer families are needed
to confirm this observation as well as to determine if
screening for PALB2 is needed regardless the status of
BRCA1, BRCA2, and other genes that predispose individuals to breast cancer. Such a large-scale screen would
allow for the entire spectrum of PALB2 mutations to be
mapped in order to reveal their roles in familial breast
cancer.
Exome data used in this analysis were also used in our
previous studies. As such, a logical question arises; why
were these mutations in PALB2 not identified in the previous studies? Our analysis of the mapping data shows that
most of the PALB2 variants called in current study had
lower sequence coverage, which is a known phenomenon
for exome sequence data [25]. Similarly, these variants
were under the threshold for variant call conditions used in
our previous studies. Thus, focusing on PALB2-mapped
sequences, lowering the cut-off values for variant calls, and
using Sanger sequencing for validation allowed us to
identify missed variants. Notably, an extensive amount of
exome data has been generated from breast cancer genomic
studies [26, 27]. Our study shows that targeted mining of
existing exome data plus Sanger validation is a powerful
approach to identify the mutations in specific genes. In
summary, our study shows that mutations in PALB2 can
occur independent of the status of BRCA1 mutations.
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Chan T, Kwong A, Barkardóttir R, Radice P, Peterlongo P, Devilee
P, Hilbers F, Benitez J, Kvist A, Törngren T, Easton D, Hunter D,
Lindstrom S, Kraft P, Zheng W, Gao YT, Long J, Ramus S, Feng
BJ, Weitzel JN, Nathanson K, Offit K, Joseph V, Robson M,
Schrader K, Wang S, Kim YC, Lynch H, Snyder C, Tavtigian S,
Neuhausen S, Couch FJ, Goldgar DE (2013) COMPLEXO: identifying the missing heritability of breast cancer via next generation
collaboration. Breast Cancer Res 15(3):402

123
All in-text references underlined in blue are linked to publications on ResearchGate, letting you access and read them immediately.

